Negative Regulation Of Nk Cell Activation By Cbl-B And Tam Receptors by Chirino, Leilani Marie
University of Pennsylvania 
ScholarlyCommons 
Publicly Accessible Penn Dissertations 
2019 
Negative Regulation Of Nk Cell Activation By Cbl-B And Tam 
Receptors 
Leilani Marie Chirino 
University of Pennsylvania 
Follow this and additional works at: https://repository.upenn.edu/edissertations 
 Part of the Allergy and Immunology Commons, Biochemistry Commons, Immunology and Infectious 
Disease Commons, Medical Immunology Commons, and the Molecular Biology Commons 
Recommended Citation 
Chirino, Leilani Marie, "Negative Regulation Of Nk Cell Activation By Cbl-B And Tam Receptors" (2019). 
Publicly Accessible Penn Dissertations. 3674. 
https://repository.upenn.edu/edissertations/3674 
This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/3674 
For more information, please contact repository@pobox.upenn.edu. 
Negative Regulation Of Nk Cell Activation By Cbl-B And Tam Receptors 
Abstract 
Natural Killer (NK) cells are innate immune cells equipped with the ability to rapidly kill stressed cells that 
are neoplastic or virally-infected. NK cells are especially important in settings where these stressed cells 
down-regulate MHC class I molecules and evade recognition by cytotoxic T cells. However, the activity of 
NK cells alone is often suboptimal to fully control tumor growth or to clear viral infections. Thus, the 
enhancement of NK cell function is necessary to fully harness their anti-tumor or anti-viral potential. TAM 
receptors (Tyro3, Axl, and Mer) are receptor tyrosine kinases (RTKs) that are expressed by multiple 
immune cells including NK cells. Although RTKs typically enhance cellular functions, TAM receptor 
ligation blocks NK cell activation. The mechanisms by which RTKs block NK cell signaling downstream of 
activating receptors are unknown. We demonstrate that TAM receptors attenuate NK cell responses via 
the activity of the E3 ubiquitin ligase Cbl-b. Specifically, we show that Tyro3, Axl, and Mer phosphorylate 
Cbl-b, and Tyro3 ligation activates Cbl-b by phosphorylating tyrosine residues 133 and 363. Ligation of 
TAM receptors by their ligand Gas6 suppresses activating receptor-stimulated NK cell functions, such as 
IFNγ production and degranulation, in a TAM receptor kinase- and Cbl-b-dependent manner. Moreover, 
Gas6 ligation induces the degradation of LAT1, a transmembrane adaptor protein required for NK cell 
activating receptor signaling, in WT but not in Cbl-b knock-out (KO) NK cells. Together, these results 
suggest that TAM receptors may attenuate NK cell function by phosphorylating Cbl-b, which in turn 
dampens NK cell activation signaling by promoting the degradation of LAT1. Our data, therefore, support 
a mechanism by which RTKs attenuate, rather than stimulate, signaling pathways via the activation of 
ubiquitin ligases. Based on our findings, the TAM/Cbl-b pathway has key molecules that can be targeted 
therapeutically for the treatment of cancers and viral infections. In collaboration with Progenra, Inc, we 
tested several novel small molecule inhibitors that target Cbl-b. Several of the inhibitors tested enhanced 
NK and T cell effector functions. One inhibitor tested in vivo did not have any effect in decreasing tumor 
burden, likely due to the poor half-life of the in vivo formulation. More inhibitors in development will be 
tested in the future. These inhibitors provide a promising novel therapeutic strategy to enhance NK and T 
cell activation in the setting of a variety of cancers and possibly chronic viral infections. 
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ABSTRACT 
 
NEGATIVE REGULATION OF NK CELL ACTIVATION BY CBL-B AND TAM 
RECEPTORS 
Leilani M. Chirino 
Taku Kambayashi  
Natural Killer (NK) cells are innate immune cells that rapidly kill stressed cells that are 
neoplastic or virally-infected. NK cells are crucial in settings where these stressed cells 
down-regulate MHC class I molecules and evade recognition by cytotoxic T cells. 
However, the activity of NK cells alone is often suboptimal to fully control tumor growth 
or to clear viral infections. Thus, the enhancement of NK cell function is necessary to 
fully harness their anti-tumor or anti-viral potential. TAM receptors (Tyro3, Axl, and Mer) 
are receptor tyrosine kinases (RTKs) that are expressed by multiple immune cells 
including NK cells. Although RTKs typically enhance cellular functions, TAM receptor 
ligation blocks NK cell activation. The mechanisms by which RTKs block NK cell 
signaling downstream of activating receptors are unknown. We demonstrate that TAM 
receptors attenuate NK cell responses via the activity of the E3 ubiquitin ligase Cbl-b. 
Specifically, we show that TAM receptors phosphorylate Cbl-b, and Tyro3 ligation 
activates Cbl-b by phosphorylating tyrosine residues 133 and 363. Ligation of TAM 
receptors by their ligand Gas6 suppresses activating receptor-stimulated NK cell 
functions, such as IFNγ production and degranulation, in a TAM receptor kinase- and 
Cbl-b-dependent manner. Moreover, Gas6 ligation induces the degradation of LAT1, a 
transmembrane adaptor protein required for NK cell activating receptor signaling, in WT 
but not in Cbl-b knock-out (KO) NK cells. Together, these results suggest that TAM 
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receptors may attenuate NK cell function by phosphorylating Cbl-b, which in turn 
dampens NK cell activation signaling by promoting the degradation of LAT1. Based on 
our findings, the TAM/Cbl-b pathway has molecules that can be targeted therapeutically 
for the treatment of cancers and viral infections. In collaboration with Progenra, Inc, we 
tested several novel small molecule inhibitors that target Cbl-b. Several of the inhibitors 
enhanced NK and T cell effector functions. One inhibitor tested in vivo did not decrease 
tumor burden. More inhibitors in development will be tested in the future. These 
inhibitors provide a promising novel therapeutic strategy to enhance NK and T cell 
activation in the setting of a variety of cancers and possibly chronic viral infections. 
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CHAPTER 1: Introduction1 
The Innate Immune System  
 
The human body has two lines of defense against foreign pathogens and tumors 
- the innate and adaptive immune systems. The innate immune system is the first 
responder- both fighting the infection and helping induce the adaptive immune system. 
This first response relies on the recognition of foreign pathogens and tumor cells by 
germline-encoded receptors of innate immune cells, whereas the adaptive immune 
system uses variable antigen-specific receptors[1]. These receptors are a result of gene 
segment rearrangements. Without an innate immune response, the body becomes 
susceptible to infection despite having an intact adaptive immune system.  
The first barrier to a pathogen is the skin; however, as soon as a pathogen 
infiltrates the skin, the first response by the innate immune system begins with 
preformed molecules[1]. These include antimicrobial enzymes and peptides that break 
down bacterial cell walls and membranes, respectively, in addition to the complement 
system - a group of plasma proteins that targets pathogens for lysis and phagocytosis[1]. 
After this first phase, cells of the innate immune response sense these proteins as 
foreign to the host. Three key players of the second phase of the innate immune 
response include dendritic cells (DCs), macrophages, and natural killer (NK) cells.  
Dendritic cells (DCs) are antigen-presenting cells that act as messengers 
between the innate and adaptive immune systems. Their main function is to process 
antigens and present it on their cell surface to T cells - a diverse class of adaptive 
 
1 Portions of this chapter have been previously published as: Freund-Brown, J, Chirino, L, & 
Kambayashi, T. Strategies to Enhance NK Cell Functions for the Treatment of Tumors and 
Infections. Critical Reviews in Immunology. 38(2): 105-130 (2018). 
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immune cells with an array of effector functions[1]. DC presentation of antigen to T cells 
activates naive T cell signaling. Macrophages are cells that engulf and digest cellular 
debris, foreign substances, microbes, cancer cells, and anything else that does not have 
proteins specific to healthy cells on its surface in a process called phagocytosis[1]. 
Phagocytic cells not only kill invaders but also recruit other immune cells with effector 
responses that are appropriate for the task at hand. These cells help maintain normal 
immune homeostasis in the face of constantly changing microbes in the environment.  
The focus of this thesis is on NK cells. NK cells are another type of innate 
immune cell that were first described in the 1970s as large granular lymphocytes with 
the ability to spontaneously kill tumor cell lines[2]. This killing was different from that 
performed by cytotoxic T cells (CD8+ T cells), as the eradication of tumor cells by NK 
cells occurred without previous exposure to the tumor (priming). CD8+ T cells are a 
subclass of T cells that kill virus-infected and tumor cells that express MHC class I (MHC 
I), and they require prior exposure to the antigen before making enough T cells to fight 
the tumor[1].  
As opposed to T cells that recognize target cells through their unique T-cell 
receptor created by gene rearrangement, NK cells express several germline-encoded 
activating and inhibitory receptors that bind to stress proteins, viral proteins, IgG Fc, and 
MHC I molecules[3]. It is the balance of the signals that are generated from the ligation 
of numerous activating and inhibitory receptors that dictates the activation of NK cells. 
One key aspect of NK cell function is their ability to kill cells that have down-regulated 
MHC I, a process known as “missing-self” recognition[4],[5]. As NK cells express 
inhibitory receptors that bind to MHC I molecules, cells with down-regulated MHC I 
disinhibit NK cells and become targets of NK cell-mediated cytotoxicity. This is an 
important function of NK cells as tumor cells and virally infected cells often down-
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regulate MHC I molecules to evade recognition by CD8+ T cells. Thus, NK cells can 
complement the activity of CD8+ T cells that can no longer recognize and kill such cells. 
 
Strategies to enhance NK cell function for the treatment of tumors and infections 
 
NK cells use similar effector functions as CD8+ T cells. NK cells kill target cells 
through the release of granules, which contain proteins such as perforin and granzymes. 
Perforins form pores in the cell membrane of a target cell, allowing granzymes to travel 
into its cytoplasm and induce apoptosis by damaging key processes for cell survival[6]. 
Another important function of an NK cell is the production of inflammatory cytokines, 
such as interferon-gamma (IFNγ) and tumor necrosis factor alpha (TNFα). These 
cytokines recruit T cells to the site of infection or malignancy and impact the function and 
maturation of myeloid cells[1]. 
In addition to CD8+ T cells, harnessing the cytotoxic potential of NK cells to fight 
tumors and viral infections may be beneficial for many reasons. 1) NK cells are able to 
eliminate transformed cells and virally infected cells in an MHC I/antigen-independent 
manner, 2) NK cells are activated and respond to a variety of different stimuli, including 
stress-induced proteins, mismatched MHC I, and missing/down-regulated MHC I, 3) 
cancers and viral infections have developed evasion tactics to avoid T cell recognition 
(such as the down-regulation of MHC I), and lastly 4) NK cells potentially cause less 
immunopathology, such as immunopathology induced by graft-versus-host disease 
(GVHD), compared to T cells[7]. Thus, the enhancement of NK cell function is an 
attractive therapeutic strategy against tumors and viral infections. 
Currently, NK cell-based therapies have failed in clinical trials for multiple 
reasons, mainly technical. There have been technical difficulties growing them ex vivo, 
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and once infused into patients, they often do not persist and expand and have 
suboptimal effector functions[8]. However, because they are safer to use than T cells, it 
is worth developing strategies to enhance NK cell function for therapies.  
The enhancement of NK cell function can be accomplished in a variety of ways. 
Three major strategies include: 
1. Targeting inhibitory signaling pathways and negative regulators of NK cell 
activating signaling pathways.  
2. Manipulation of inhibitory/activating receptors expressed by NK cells. 
3. Cytokine-mediated activation and expansion of NK cells. 
NK cells are stimulated or inhibited by ligation of transmembrane receptors. These 
receptors assemble signaling molecules that distribute a signal, which determines the 
function of the cell[3]. For this thesis, we have focused on studying inhibitory signaling 
pathways and negative regulators of NK cell signaling, the latter which may inhibit a 
signal by limiting the lifetime of these multiprotein signaling complexes.  
NK cell activation  
 
When an NK cell engages a target cell, the NK cell receives both activating and 
inhibitory signals from a variety of ligands expressed by the target cell. When interacting 
with an unstressed healthy cell, NK cells are not activated because the net activating 
and inhibitory inputs the NK cell receives are balanced. However, tumor cells and a 
variety of infected cells often increase activating ligands (e.g., NKG2D ligands) and/or 
decrease inhibitory ligands (e.g. MHC I) on their cell surface. In these scenarios, the NK 
cell is activated by the increase in activating signals and/or a decrease in inhibitory 
signals it receives from the target cell. Thus, it is plausible that NK cell function could be 
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further enhanced by the pharmacological blockade of inhibitory signals or negative 
regulators.  
Compared to T cells, the signal transduction pathways leading from NK cell 
activating receptors are more complex. In part, this complexity stems from the fact that 
NK cells use multiple activating receptors to detect their targets. Activating NK cell 
receptors such as NK1.1, CD16, and activating killer-cell immunoglobulin-like receptors 
(KIRs) or Ly49 receptors utilize immunoreceptor tyrosine-based activation motif (ITAM)-
containing adaptor molecules, such as DNAX-activating protein of molecular mass 12 kD 
(DAP12), CD3ζ, and FcεRγ to initiate signal transduction[9]. Other activating receptors, 
such as NKG2D and 2B4, use YxxM motif-containing costimulatory adaptors and SAP, 
respectively, to transduce their signals[3]. Although these activating receptors initiate 
signal transduction through different proximal mechanisms, many of the critical signaling 
pathways are shared and regulated in a similar manner. For example, we previously 
reported that the signaling and NK cell function downstream of all three of these 
activating receptor families converge upon the adaptor molecule known as SLP-76[10]. 
Some of the key distal signaling pathways that emanate from SLP-76 include the 
activation of phosphoinositide 3-kinases (PI3K)s, Vav, and phospholipase C (PLC)γ - all 
molecules required for NK cell effector functions (Fig. 1.1).  
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PI3Ks are lipid kinases that regulate a wide variety of signaling pathways 
downstream of immunoreceptor engagement. When activated, PI3Ks are recruited to the 
plasma membrane where they phosphorylate the membrane-associated lipid molecule 
PtdIns(4,5)P2 (PIP2) to form PtdIns(3,4,5)P3 (PIP3). PIP3 molecules can then localize 
plextrin homology (PH) domain-containing proteins to the plasma membrane, allowing 
for protein-protein interactions to occur[3],[11]. One critical signaling molecule that is 
FIGURE 1.1 The manipulation of NK cell signaling pathways and the removal of negative 
regulators of NK cell activation signaling pathways may enhance NK cell cytotoxicity and 
cytokine production. This figure depicts both the critical signaling pathways downstream of 
activating receptors that drive NK cell effector functions and those that inhibit it. Activating receptors 
converge on SLP-76, which drives the activation of PLCγ, Vav, and PI3K. Downstream signals 
emanating from these enzymes are critical for NK cell cytotoxicity and inflammatory cytokine 
production. Negative regulators of these pathways are depicted by yellow stars. The disruption of 
negative regulators of proximal signaling pathways or those directly associated with inhibitory 
receptor function (PTEN, SHIP, and SHP-1) results in hyporesponsive NK cells. In contrast, 
targeting negative regulators of distal signaling pathways that are not directly associated with 
inhibitory receptor function (DGKζ, Cbl) result in enhancement of NK cell function. Modified from 
Freund-Brown, J Chirino, L and Kambayashi, T, Strategies to enhance NK cell function for the 
treatment of tumors and infections. Crit Rev Immunol. 38: 105-130 (2018). Copyright 2018. Begell 
House, Inc.  
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activated by PIP3 is AKT. PIP3 allows the co-localization of AKT and its kinase PDK-1 
through their PH domains, leading to AKT phosphorylation[11]. 
Class I PI3Ks are heterodimeric proteins comprised of a p85 (regulatory) and 
p110 (catalytic) subunit. Both p85 and p110 subunits have several isoforms with varying 
functions[11]. The p110δ isoform has been suggested to be critical for NK cell 
production of IFNγ, GM-CSF, MIP1α, and MIP1β[12]. Moreover, p110δ-PI3K is important 
for the elimination of BCR/ABL+ leukemic cells, and NK cells lacking PI3K had defects in 
Ca2+ mobilization following ionomycin stimulation. Thus, PI3K-p110δ may play a general 
role in promoting Ca2+-triggered exocytosis, which would impact both degranulation and 
cytokine secretion[13]. Furthermore, PI3K-induced mammalian target of rapamycin 
(mTOR) signaling is important following NK cell IL-15 priming. IL-15 priming of NK cells 
enhances their functional capacity including the expression of cytotoxic granules and an 
increased IFNγ response[14]–[16]. Pharmacological inhibition of PI3K, mTOR, and AKT 
inhibits IFNγ production following IL-15 priming of stimulated NK cells. PI3K signals are 
also crucial for the proliferation and granzyme B expression of IL-15-primed NK cells 
during murine cytomegalovirus infection[17]. 
Negative regulation of NK cells  
 
NK cells have several intracellular negative regulators to prevent over-activation 
downstream of activating receptors and thus prevent autoimmunity. The phosphatase 
and tensin homolog (PTEN) and the SH2 domain-containing inositol 5'-phosphatase 
(SHIP) are negative regulators of the PI3K pathway. PTEN and SHIP are lipid 
phosphatases that dephosphorylate PtdIns(3,4,5)P3 to PtdIns(4,5)P2 and PtdIns(3,4)P2, 
respectively, thereby decreasing the levels of PIP3. Given the positive role that PI3K 
plays in NK cell cytotoxicity and cytokine production, PTEN and SHIP would be expected 
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to inhibit these functions. However, PTEN conditional KO[18] and SHIP1-deficient[19] 
NK cells did not produce more IFNγ in response to cytokine stimulation or anti-NK1.1 
stimulation. These data suggest that removing a negative regulator of PI3K signaling, 
such as PTEN or SHIP, may result in loss and not enhancement of NK cell effector 
function. Another potential target is DAG kinase (DGK), which is a family of negative 
regulators of the DAG signaling pathway (Fig. 1.1). DAG is created when active PLCγ 
cleaves PIP2 into IP3 and DAG[3],[20]. The generation of IP3 increases intracellular Ca2+ 
levels and subsequent activation of Ca2+-dependent processes. DAG directly activates 
PKC family members and Ras guanyl nucleotide-releasing protein (RasGRP), leading to 
downstream activation of pathways such as ERK, NFκB, and AKT[21],[22]. DGK 
enzymes phosphorylate DAG into phosphatidic acid (PA), thereby regulating the balance 
of IP3 and DAG signaling in a cell[23].  
Our lab has shown that DGKζ KO mice displayed enhanced degranulation and 
IFNγ production compared to WT NK cells following activating receptor stimulation in 
vitro[24]. Moreover, DGKζ KO NK cells also displayed significantly enhanced cytotoxicity 
against the NK cell-sensitive tumor cell line YAC-1. Thus, therapeutic targeting of distal 
negative regulators of NK cell activation, such as DGKζ, may represent a strategy for 
improving the clinical efficacy of NK cells. 
Ubiquitin ligases as targets to enhance immune cell function  
 
In this thesis, we are focusing on another strategy to enhance NK cell activation 
by targeting a different type of negative regulator: E3 ubiquitin ligases. E3 ubiquitin 
ligases are a large family of proteins that function downstream of several receptor-
signaling pathways during the regulation of cell proliferation and survival. They are 
engaged in the regulation of the turnover and activity of many proteins, making them 
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potential intracellular targets for enhancing NK cell function (Fig. 1.1). In addition, there 
is evidence to suggest that the abnormal regulation of some E3 ligases is involved in the 
development of various cancers[25]. Furthermore, some E3 ubiquitin ligases are 
frequently overexpressed in human cancers, correlating with an increased rate of 
chemoresistance and a poor clinical prognosis[25]. 
Ubiquitination is one of many posttranslational modifications that impact signaling 
thresholds in immune cells in a variety of ways, e.g. by targeting proteins for degradation 
or recruiting ubiquitin-binding proteins[26]. Ubiquitination of a substrate requires the 
sequential action of 3 classes of enzymes: E1 or ubiquitin activating enzyme, E2 or 
ubiquitin conjugating enzyme, and an E3 ubiquitin ligase. In the ubiquitination pathway, 
E1 activates ubiquitin by the formation of a thioester with the carboxyl group of glycine 
76 on ubiquitin[27]. The ubiquitin is then transferred to a catalytic cysteine on an E2, 
which then associates with an E3 that is in a complex with a substrate protein. The E3 
may serve as a scaffold to facilitate the transfer of ubiquitin from the E2 to the substrate, 
as is the case for the RING (Really Interesting New Gene) type of E3 ubiquitin 
ligases[28],[29]. E3 ligases can thus identify the substrate and also dictate the formation 
of ubiquitin linkages, driving the mono, multi-mono, or polyubiquitination of the 
substrate.  
Ubiquitin has seven accessible lysines on its surface (K6, K11, K27, K29, K33, 
K48, or K63), each of which can be a point of attachment for ubiquitin chains[30]. The 
amino terminal methionine of ubiquitin (M1) can also serve as a point of attachment for 
linear chains in a reaction catalyzed by an E3 ubiquitin ligase complex called the linear 
ubiquitylation assembly complex (LUBAC)[31]. These ubiquitin chains can subsequently 
determine the fate of a substrate by changing its location in the cell, promoting or 
inhibiting its interactions with other proteins, or driving degradation by the lysosome or 
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proteasome. Ubiquitination is a dynamic and reversible event because ubiquitin chains 
can be cleaved by a family of ubiquitin-specific proteases called deubiquitinating 
enzymes (DUBs)[25].  
The Cbl (Casitas B-lineage lymphoma proto-oncogene) family of proteins is 
comprised of E3 ubiquitin ligases that negatively regulate several tyrosine kinase-
dependent pathways and are, therefore, targets to enhance immune cell functions. This 
family includes the homologs c-Cbl and Cbl-b, which are expressed in a variety of 
immune cells. c-Cbl and Cbl-b share a highly conserved N-terminal tyrosine kinase 
binding (TKB) domain, a RING finger (RF) domain, and a linker domain that connects 
the TKB and RF domains (Fig.1.2). The modified SH2 domain within the TKB 
recognizes phosphorylated tyrosines on substrate proteins[32]. The linker domain 
contains tyrosine residues that are crucial to the regulation of Cbl’s E3 function, and the 
RF domain is the catalytic domain that binds to ubiquitin-conjugating enzyme 
E2[33],[34]. This RF domain mediates the transfer of ubiquitin directly from the 
associated E2 to one or more lysines of the specific target protein, which provides 
specificity to the ubiquitination process. c-Cbl and Cbl-b differ in their C-termini, which 
mainly determines ubiquitin-independent functions of Cbl proteins. The C-termini include 
proline-rich domains, tyrosines, and ubiquitin associated (UBA) domains; the latter of 
which mediate other protein interactions with SH2 and SH3 domain-containing proteins, 
enabling diversity in signaling[35]. These carboxy-terminal interactions are involved in 
the control of cell-specific functions of Cbl, including the uptake of glucose, activation of 
osteoclasts, remodeling of bone, and cell migration[36]–[38].  
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The many roles of Cbl proteins   
 
Cbl proteins can function as inhibitors, adaptors, or E3 ligases. c-Cbl binds to 
Grb2, competing with and preventing binding of the guanine-nucleotide exchange factor 
son-of-sevenless (SOS), blocking signaling through the Ras-mitogen-activated protein 
kinase (MAPK) pathway and inhibiting proliferation. Independent of their ubiquitin ligase 
activity, Cbl proteins can also act as adaptor proteins, specifically via their proline-rich C-
termini where molecules with SH2 and SH3 domains can bind[39]. As an adaptor, c-Cbl 
recruits other adaptor molecules, such as Cbl-interacting protein of 85 kDa (CIN85) and 
CD2AP, which trigger signaling cascades that lead to endocytosis by dynamin-
dependent, clathrin-mediated receptor endocytosis[40]. They can also recruit molecules 
to activated receptor tyrosine kinases (RTKs). In T cells, c-Cbl has been shown to recruit 
active p85 to the plasma membrane, which subsequently activates the PI3K/AKT 
pathway[41],[42]. Cbl-b was also found to bind p85 via its proline-rich sequence, 
FIGURE 1.2. Structure, interaction, and regulation of Cbl-b. The tyrosine kinase-binding 
(TKB) domain targets phosphorylated tyrosines on tyrosine kinases. Cbl-b becomes 
phosphorylated on tyrosine 363 located in the linker regions. E2 binds to the RING finer (RF) 
domain. Other proteins regulated by Cbl-b, such as Vav and p85 bind within the proline-rich (PR) 
region. (EGFR, epidermal growth factor receptor; CIN c-Cbl- interacting protein; EGFR, epidermal 
growth factor receptor; UBA, ubiquitin- associated; ZAP-70, ζ-chain-associated protein kinase 
70.)  
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independent of the TKB[43] (Fig.1.2). Interestingly, p85 was still ubiquitinated, showing 
that Cbl-b’s role as an adaptor and E3 ubiquitin ligase are not mutually exclusive[44]. 
Whether Cbl proteins act as adaptors or ligases is likely cell- and context-dependent.  
Cbl’s E3 ligase activity is essential for the negative regulation of signaling 
molecules. The type and length of ubiquitination determines the outcome of the 
substrate.  Substrates can either be tagged with single (monoubiquitination) or multiple 
(>4) ubiquitins, which leads to polyubiquitination. Monoubiquitination typically disrupts a 
signaling complex formation by preventing binding of the ubiquitinated protein. However, 
monoubiquitylation is also thought to be sufficient as an internalization signal, whereas 
the addition of four or more ubiquitin molecules is required for recognition by the 
proteasome[44]. The polyubiquitin chains are generally linked by lysine residues at 
position 48 or 63, and this polyubiquitination induces their degradation by the 26S 
proteasome, but polyubiquitin chains may also modify protein function, e.g. by increased 
cell-surface receptor turnover or a change in location. Monoubiquitination, on the other 
hand, targets cell membrane-receptor associated proteins to the lysosome, attenuating 
cell surface mediated signals by a desensitization process. Thus, monoubiquitination 
and K63-linked polyubiquitination regulate protein trafficking and cell to cell interactions, 
whereas K48-linked polyubiquitination targets substrates to the proteasome for 
degradation[45]. The activation of Cbl and the subsequent ubiquitination of key signaling 
molecules can acutely lower the number of these molecules (via degradation) or make 
them inactive/unusable (via altered localization or binding), thereby functioning as a 
feedback mechanism to attenuate further signaling[40].  
 c-Cbl and Cbl-b seem to differ in the outcome of their E3 ubiquitin ligase activity. 
In c-Cbl, ubiquitination often results in degradation, whereas Cbl-b ubiquitination tends to 
affect protein localization and associations[40]. For example, Cbl-b is known to poly-
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ubiquitinate the p85 subunit of PI3K, preventing its binding to CD28 and decreasing T-
cell anti-tumor activity[43]. However, this generalization does not always hold true, as 
Cbl-b has been shown to ubiquitinate and degrade the epidermal growth factor receptor 
signaling complex[46].  
 
Regulation of Cbl proteins  
 
Typically, Cbl proteins are found in the cytosol in an autoinhibited state where the 
N-terminal TKB domain masks the RF domain, making them catalytically inactive[47]. 
Phosphorylation of Y363 on Cbl-b, located in the linker region between TKB and RF 
domains, regulates the E3 activity of Cbl-b by 2 mechanisms: one by physically 
separating the RF domain from the TKB domain, and the other by forming a surface to 
enhance binding affinity to E2s[47] (Fig.1.2). Consistent with these findings, the 
equivalent tyrosine in c-Cbl, i.e., Y371, has been shown to regulate its E3 ubiquitin 
ligase activity in a similar fashion[48],[49]. Both Cbl-b and c-Cbl’s tyrosine residues are 
phosphorylated by Syk and some members of the Src-like family of kinases[44],[50]. 
PKCθ activity has also been shown to modulate the strength of T cell signaling by 
phosphorylating Cbl-b, targeting it for degradation[51]. There are likely many other 
kinases that phosphorylate and regulate Cbl proteins that have yet to be identified.  
There are examples of phosphorylation that does not lead to degradation. GSK-3 
has been shown to phosphorylate Cbl-b on serine residues 476 and 480, which leads to 
stabilization of Cbl-b levels and constraint of T cell signaling[52]. This suggests that the 
fate of Cbl proteins after being phosphorylated is likely residue- and location-dependent.  
Too much negative regulation of immune cells can lead to their lack of activation 
in the face of a cancerous or virally-infected cell. Therefore, there are mechanisms in 
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place to negatively regulate E3 ubiquitin ligases like Cbl. Cbl has been reported to be 
degraded along with its substrates EGFR and KIT[46],[53],[54]. In both cases, the 
degradation of the receptor and Cbl protein was dependent on the RING domain of the 
E3, suggesting that Cbl proteins regulate themselves via auto-ubiquitination and 
degradation. Not only may these mechanisms serve to circumvent autoimmunity but also 
may serve to avoid undesired targeting of other substrates by the activated Cbl. This 
ensures that specificity of the signaling pathway is maintained[55].  
Cbl proteins are also regulated by other E3 ubiquitin ligases. NEDD4 directly 
ubiquitinates Cbl-b in vitro, and both Nedd4 and Itch stimulate the degradation of Cbl-b 
and c-Cbl[56]. Cbl-b degradation by Nedd4 appears to be induced by T-cell activation 
where co-stimulation of resting T cells by CD3 and CD28 results in a rapid degradation 
of Cbl-b, which is dependent on Nedd4[57].  
 
Cbls as regulators of T cell effector functions  
 
There is more known about the role of Cbl proteins in T cells than in NK cells. 
The importance of c-Cbl and Cbl-b in immunity and immune receptor signaling pathways 
was initially demonstrated by the phenotypes of the mice lacking each respective gene. 
c-Cbl and Cbl-b single KO mice are viable, whereas double KO are embryonically 
lethal[58], suggesting they have overlapping functions. Consistent with their roles as 
negative regulators, both c-Cbl KO and Cbl-b KO mice display hyperactive signaling 
downstream of the TCR. A characteristic feature of these mice is that loss of either Cbl 
protein lowers the activation threshold for signaling through the TCR. This leads to 
hypersensitivity to low affinity and avidity engagement of the TCR, as well as activates 
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downstream signaling pathways without the usual requirement for co-receptor 
stimulation[59].  
 Despite the similar T cell effector outcomes, the phenotypes of c-Cbl KO and 
Cbl-b KO mice are different, likely due to their tissue distribution. c-Cbl is expressed 
more in the thymus compared to Cbl-b, which is expressed more in peripheral T 
cells[36]. As such, c-Cbl KO T cells display an increased number of thymocytes and 
enhanced TCR signaling, likely due to CD4+ and CD8+ double positive thymocytes 
having increased levels of CD3, TCR-β, TCR-δ, Lck, and FynT[36]. Cbl-b KO mice 
develop autoimmunity from increased peripheral T cell proliferation and enhanced 
cytolytic activity of CD8+ T cells without requiring CD28 co-stimulation[36],[59]. This 
suggests that Cbl-b plays a critical role in T cell tolerance induction. As such, Cbl-b 
negatively regulates the costimulatory pathway of CD8+ T cells, functioning as a central 
gatekeeper of T-cell activation. 
 Mice lacking Cbl-b were found to be less susceptible to tumor formation in 
induced as well as spontaneous mouse models of cancer, and this effect was found to 
be mediated by CD8+ T cells[60]. The loss of Cbl-b was found to enhance antitumor 
reactivity of CD8+ T cells even in the absence of CD4+ T cells. Lack of Cbl-b led to a 
significant delay in tumor growth in both a mouse model of lung cancer where TC-1 
tumors were subcutaneous implanted as well as in a model of spontaneous tumors by 
UV irradiation. Tumor rejection correlated with increased infiltration of CD3+CD8+ T cells 
into the tumor[60]. Increased tumor infiltration of CD8+ T cells also led to a significant 
increase in IFNγ production within the tumor microenvironment, reflecting an enhanced 
immune response in vivo.  
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Based on these findings, the Cbl family was determined from early on to be 
regulators of immunoreceptor families, in particular, T cell and B cell antigen receptors. T 
and B lymphocytes recognize antigens through their TCR and BCR, respectively. 
Following initial triggering of the antigen receptor, the Src family kinases Lck and Fyn are 
recruited and phosphorylate Zap-70, which initiates various downstream signaling 
pathways. ZAP-70 phosphorylates SLP-76, mediating the formation of a multi-subunit 
protein complex including key signaling molecules, such as PI3K, PLC, and Vav1[61].  
Activation of these signaling components results in activation of PLCγ-regulated calcium 
influx, cytoskeletal rearrangements via Vav1, Rac, and WASP, and activation of 
PKCθ[62]. The activation step of PKCθ is essential for an appropriate NFκB stimulation 
to induce a productive T cell response in vivo[63]. Upon TCR or BCR stimulation, c-Cbl 
is recruited to the plasma membrane by Src-like adaptor proteins (SLAP) where it can be 
phosphorylated by Src-like and Syk-like kinases[64]. c-Cbl can then ubiquitinate key 
signaling molecules, including Src, Lck, ZAP-70, LAT, and p85[65]–[69]. Not only do Cbl 
family proteins ubiquitinate these downstream signaling molecules, but both c-Cbl and 
Cbl-b have also been shown to silence TCR signaling by internalization of the receptor 
complex[58].   
Despite all these studies, how Cbl-b was regulating immune cell effector 
functions via these proteins was unknown. There were several clues that Cbl-b’s 
physiological functions is mediated by its E3 ligase activity. For example, the RING 
finger domain of Cbl proteins is evolutionarily conserved[70], and this domain is directly 
responsible for protein ubiquitylation[71],[72]. Therefore, not surprisingly, Cbl-b E3 
ligase-defective (C373AKI/KI) mice phenocopy the T cell responses observed in the Cbl-b 
KO mouse described above, resulting in T cell hyperactivation, spontaneous 
autoimmunity, and impaired induction of T cell anergy in vivo[73]. Moreover, mice 
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carrying a Cbl-b E3 ligase-defective mutation spontaneously reject tumor cells that 
express human papilloma virus antigens[73].   
The role of c-Cbl and Cbl-b in NK cells  
 
Although less well-studied, NK cells are also regulated by Cbl proteins. The role 
of c-Cbl in NK cell cytotoxicity and cytokine production has been explored in a human 
NK cell line (NKL cells). Upon NKG2D and 2B4 co-ligation, NKL cells with reduced levels 
of c-Cbl (by siRNA knock-down) displayed enhanced cytotoxic responses and IFNγ 
production[74]. In addition, whereas NKG2D ligation alone does not normally induce 
IFNγ production by NKL cells, NKG2D stimulation alone was sufficient to elicit IFNγ 
production in NKL cells with reduced c-Cbl expression[74]. The enhancement in NKL cell 
function by c-Cbl knockdown was associated with decreased Vav ubiquitination in these 
cells, suggesting that Vav ubiquitination may represent the mechanism for c-Cbl–
mediated inhibition. However, how exactly c-Cbl regulates Vav-mediated signaling is still 
unclear, since the knockdown of c-Cbl did not appreciably alter the level of total Vav or 
phosphorylated Vav proteins[74].  
Although originally considered to be a regulator of TCR signaling, Cbl-b KO mice 
spontaneously rejected tumors even on a recombination-activating gene 2 (RAG2) KO 
background[75]. This effect was lost when NK cells were depleted or when NKG2D was 
blocked, suggesting that Cbl-b KO NK cells also display enhanced anti-tumor activity. In 
addition, metastatic tumor burden was significantly reduced when NK cells from Cbl-b 
KO and Cbl-b ligase mutant (C373AKI/KI) mice were adoptively transferred to a NeuT 
metastatic breast cancer model[75]. Together, these data suggest that Cbl-b negatively 
regulates NK cell function through its ubiquitin ligase domain.   
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Cbl-b KO NK cells display enhanced proliferation, degranulation, and IFNγ 
secretion in vitro, but how Cbl-b negatively regulates NK cell function is not entirely 
clear. Which substrates Cbl-b targets to inhibit NK cell function likely depends on which 
receptors are stimulated on the NK cell surface. KIR activation recruits SH2-domain-
containing protein tyrosine phosphatase-1 (SHP-1) and SHP-2, which dephosphorylates 
Vav1, LAT, PLCγ1, and PLCγ2 - all important for NK cell cytotoxicity[3]. Specifically, 
SHP-1 dephosphorylates LAT tyrosine 132, blocking recruitment and activation 
PLCγ1/2[68]. This data suggests that inhibition of NK cell effector functions depends on 
the cooperation between SHP-1 and the Cbl family. LAT ubiquitination was found to be 
dependent on its phosphorylation, which suggests that only LAT molecules that escape 
SHP-1 are targeted to be degraded[68].  In addition, both c-Cbl and Cbl-b protein levels 
were increased in human primary NK cells and in the YTS NK cell line during 
inhibition[76]. Barda-Saad’s group hypothesized that the increase in Cbl proteins allows 
for more ubiquitylation of LAT, which inhibits NK cell cytotoxicity. It is unknown, however, 
whether the elevated expression of the Cbl proteins is due to an increase in transcription 
following NK cell inhibition or due to decreased protein degradation following NK cell 
activation. 
Cbl-b and TAM receptors  
 
More recently, Cbl-b was also found to be associated with TAM receptors in an in 
vitro proteomics assay[75]. The TAM receptor family is a group of RTKs that includes 
Tyro3, Axl, and Mer[77]. Receptor tyrosine kinases are a large group of transmembrane 
proteins that translate extracellular stimuli into intracellular signals for cell proliferation, 
differentiation, survival and migration[78]–[80] (Fig. 1.2). All RTKs have a highly 
conserved cytoplasmic kinase domain that is activated upon growth factor binding to 
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receptor monomers. Activation of RTKs leads to their autophosphorylation and the 
phosphorylation of tyrosine residues of multiple downstream intracellular signaling 
molecules[81]. These are then able to initiate a variety of signal transduction cascades. 
Penninger’s group speculated that Cbl-b negatively regulates NK cells by ubiquitinating 
TAMs, which leads to their endocytosis[75]. They proposed that this endocytosed 
complex can then negatively regulate NK cell signaling. This speculation is not 
unfounded as there is evidence for Cbl proteins ubiquitinating RTKs, leading to their 
endocytosis[33].  
The carboxyl terminus of Cbl has been implicated in the control of endocytosis of 
receptor tyrosine kinases (RTKs). This has been best studied in the regulation of the 
EGF receptor. The primary mechanism of Cbl recruitment to activated EGF receptors 
involves the binding of Cbl’s SH2 domain to the auto-phosphorylated tyrosine 1045 of 
EGFR[33]. Alternatively, an EGFR Y1045F mutant could still bind Cbl, via adaptor 
protein Grb2[82]. This informs us that are multiple ways for Cbl to bind RTKs. 
Additionally, CIN85 was also shown to bind to the carboxyl terminus of Cbl, regulating 
EGF and c-MET receptor endocytosis[83],[84].  Similarly, Cbl-b mediates down-
regulation of activated EGFR and PDGFR via binding of CIN85 to the carboxyl terminus 
of Cbl-b[85].  
 
TAM receptors  
 
The TAM receptors are key regulators of homeostasis with a relevant role in 
tissue repair, vascular remodeling, and removal of apoptotic bodies[86]. Aside from a 
role in maintaining homeostasis, they have also been implicated in tumorigenesis, 
metastasis, and chemoresistance, making TAM receptors targets for therapy. In immune 
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homeostasis, they play two key roles: 1) inhibiting pro-inflammatory pathways and 2) 
promoting tissue repair after adaptive immune responses.  
Tyro3 and Axl are the most similar in genomic structures, sharing the same 
number and size of exons[87]. However, Axl and Mer have the most similar tyrosine 
kinase domain sequence[88],[89]. The human TAM receptors share 31-36% identical 
(52-57% similar) protein sequences in the extracellular regions, whereas they share 54-
59% sequence identity (72-75% similarity) in their tyrosine kinase domain[88]. The 
differences in post-translational modifications, such as glycosylation, phosphorylation, 
and ubiquitination may account for the variability in TAM expression observed across 
tissues and cell types[90],[91].  
Tyro3, Axl, Mer all share a common structure with extracellular regions 
composed of two immunoglobulin-related domains[90],[92] linked to two fibronectin type-
III repeats, and cytoplasmic regions that contain an intrinsic tyrosine kinase 
domain[93],[94],[95]. These ectodomains are hypothesized to be important in cell to cell 
contact, adhesion, and migration[77]. The kinase domain has a conserved sequence, 
including an ITIM-like sequence KW(I/L)A(I/L)ES[77]. The typical ITIM motif is 
S/I/V/LxYxxI/V/L. This motif typically becomes phosphorylated by enzymes of the Src 
kinase family, allowing them to recruit other enzymes such as the phosphotyrosine 
phosphatases SHP-1 and SHP-2 or the inositol-phosphatase SHIP[3]. These 
phosphatases decrease the activation of molecules involved in cell signaling. This may 
be one of many ways that TAM receptors can negatively regulate inflammation.  
Ligands of TAM receptors  
 
The ligands to TAM receptors include Gas6 and ProteinS[96]–[99], which bind to 
receptors with a 2:2 stoichiometry[77]. Both are glutamic acid-containing proteins that 
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are carboxylated by reduced Vitamin K. Gas6 is a growth potentiating factor[100],[101] 
which contains multiple N-terminal gamma-carboxyglutamic acid residues, four 
epidermal growth factor-like repeats and a C-terminal sex hormone-binding globular-like 
region that is sufficient for receptor activation[98]. ProteinS shares the same domain 
structure with the exception of thrombin cleavage sites, allowing it to act as an 
anticoagulant[102]. The gamma-carboxylation makes Gas6 and ProteinS biologically 
active[103] and increases their ability to bind to calcium, which is important for their 
binding to phosphatidylserine that is exposed on the surface of apoptotic cells[104]. 
Gas6 and ProteinS act as a bridge, attaching to phosphatidylserine and the TAM 
receptors, allowing for stronger signaling downstream of TAM receptors[105], as well as 
phagocytosis of apoptotic cells[77].   
Gas6 binds to all 3 TAM receptors, with a preference for Axl and Tyro3 over 
Mer[96]–[99],[106],[107], and ProteinS has preference for binding to Tyro3, followed by 
Mer but not Axl[97],[106]–[110]. Typically, Gas6 binds to a TAM receptor and activates 
the receptor via dimerization, which then elicits PI3K-AKT, MAPK, STAT and NFκB 
pathways[111]. Not only can TAMs be activated by these ligands, but they can also be 
activated via ligand-independent dimerization, ligand-dependent dimerization, 
heteromeric dimerization of two different TAM receptors, heteromeric dimerization with a 
non-TAM receptor, and trans-cellular binding of extracellular domains[77],[109]. 
TAM receptors regulate innate immune responses  
 
In hematopoietic cells, TAM receptors are primarily expressed by cells of the 
innate immune system. How TAM receptors regulate immune responses is a topic of 
immense interest, as therapeutic targets are being developed to target each individual 
receptor.  The frequently observed co-expression of the receptors and their ligands, 
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together with the presence of conserved ITIM-like domains of all 3 receptors, suggests 
that TAMs negatively regulate inflammation[112].    
TAM receptors negatively regulate innate immune responses upon activation 
with ligands Gas6 or ProteinS. It remains to be determined where the Gas6 and 
ProteinS are derived from. However, in several cell types, signaling appears to be 
autocrine or paracrine in nature[108],[113],[114]. Macrophages co-express ligands and 
receptors[115], but in NK cell activation, the data suggests that both Gas6 and ProteinS 
are present in stromal cells, and these likely stimulate the TAM receptors on NK 
cells[116]. In addition, an important source of ProteinS for TAM-expressing 
macrophages and dendritic cells may be activated T cells[117]. The latter is an elegant 
feedback mechanism, where ProteinS is only expressed in activated but not resting T 
cells, and selective deletion of T-cell derived ProteinS enhanced APC activation and 
cytokine production in an antigen-specific, TAM-RTK-dependent manner[118]. More 
recently, ProteinS was found to be produced by B6F10 melanoma cells, leading to 
reduced polarization of anti-tumor macrophages by binding to Mer and Tyro3 on the 
surface of macrophages[119].  
Regardless of the form of activation, signaling pathways downstream of TAMs 
not only control the magnitude of the immune response by dampening inflammation but 
also likely integrate the phasing out of the innate immune response.  The latter is 
accomplished by active processes that favor the resolution of inflammation and recovery 
of tissue function via the clearance of apoptotic cells and the restoration of vascular 
integrity[104]. These data suggest that TAM signaling functions at the interface of innate 
and adaptive immunity to tame the activity of innate cells and prevent unnecessary 
consequences of inflammation[120]. 
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There is clear evidence for the role of TAM receptors in dampening inflammation 
in mice lacking Tyro3, Axl, and Mer. Mice lacking all 3 TAM receptors appear normal at 
birth but develop a severe lymphoproliferative disorder accompanied by autoimmunity, 
resulting from hyperactivation of antigen-presenting cells that typically express all 3 
receptors[112]. The peripheral lymphoid organs of these mice were enlarged by 
hyperproliferation of B and T cells, which were also constitutively activated. All of these 
mice also developed autoimmunity, had elevated levels of autoantibodies, and were 
similar histologically to rheumatoid arthritis and lupus. It has been hypothesized that 
mechanistically, these phenotypes may be due to excessive activation of innate immune 
cells resulting in aberrant activation of self-reactive lymphocytes[112]. These features 
indicate that TAM receptors normally serve as a self-extinguishing regulatory 
mechanism that limits the severity and time course of inflammatory immune responses.   
TAM signaling pathways have been shown to function as negative feedback 
regulators of DC inflammation, where TAMs are only engaged after the inflammatory 
receptors, such as Toll-like (TLR) receptors, have been activated. Once the TLR is 
engaged, the first wave of pro-inflammatory cytokines is released, propagating 
inflammation by activating cytokine receptors such as type I interferon receptors 
(IFNAR)[114]. The latter then induces Axl receptor signaling. Gas6 or ProteinS-induced 
activation of Axl in APCs inhibits NFκB activation and cytokine production downstream of 
TLR3, 4, and 9[114] (Fig. 1.3).  
Not surprisingly, TAM receptors were found to be required to clear apoptotic 
bodies. The phosphatidyl serine residues on the surface membrane of apoptotic bodies 
bind to Gas6, serving as a means for recognition and subsequent phagocytosis by TAM 
receptor-expressing macrophages[121]. Thus, Tyro3, Axl, and Mer triple KO mice 
display a defect in clearing apoptotic bodies, which causes a lupus-like spontaneous 
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autoimmune disease[112]. This phenotype likely results from the accumulation of 
apoptotic cells and subsequent tissue necrosis in addition to the constitutive activation of 
the immune system[112]. Mechanistically, TAM receptors were found to mediate 
Vav1/RhoA/Rac1-dependent actin cytoskeleton rearrangements that are required for 
phagocytosis[122],[123]. Also, TAM receptors mediate the immunosuppressive effects of 
apoptosis where Mer has been shown to be essential in generating tolerogenic dendritic 
cells upon cellular apoptosis[124]. Lack of Mer generates dendritic cells that enhance T 
cell stimulation, which is associated with increased susceptibility to autoimmunity. In 
addition, TAM receptor ligation blocks pro-inflammatory cytokine release by 
macrophages[112],[114],[125]. The TAM KO mice were found to have abnormal 
regulation of cytokine release, including elevated levels of IL-12 produced by 
hyperactivated macrophages[112]. MerKD mice were also found to have elevated TNFα 
and NFκB following LPS treatment[126], suggesting that Mer is involved in attenuating a 
proinflammatory cytokine response in macrophages (Fig.1.3). 
 
 
 
FIGURE 1.3 TAM receptors can both positively and negatively regulate cells. In tumor 
cells, TAM receptor activation leads to phosphorylation of ERK and AKT, enhancing cell 
proliferation and survival. In dendritic cells, TAM receptor activation leads to 
phosphorylation of STAT1, which increases transcription of E3 ubiquitin ligases SOCS1 
and 3, inhibiting TLR and cytokine signaling. In macrophages, TAM receptor activation by 
Gas6 bridge with apoptotic cells causes phosphorylation of Vav and phagocytosis of the 
apoptotic cell.  
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Other roles for TAM receptors  
 
 Not only are TAM receptors responsible for mediating the immunosuppressive 
effects of apoptosis, they are also responsible for repairing damaged tissues. Gas6 and 
Mer contribute to tissue repair by activating the GTPase RhoA, which transcriptionally 
upregulates the hepatocyte growth factor - a key player in tissue reparation[127]. Thus, 
TAM receptors are responsible for creating an environment - both anti-inflammatory and 
reparative- to restore tissue homeostasis. 
In addition, TAM receptors control immune responses at the interface of the 
innate and adaptive immune systems[75]. Once adaptive immune cells are activated, 
they need to inform innate immune cells to prevent uncontrolled and chronic activation. 
As mentioned previously, activated T cells produce ProteinS, which binds to TAM 
receptors on dendritic cells, inhibiting DC activation, and therefore, controlling antigen-
specific immune activation[118]. TAM signaling functions bidirectionally as TAM 
receptors also directly influence T cells to control the magnitude of the adaptive immune 
response. As such, neutralization of Mer in DCs resulted in enhanced T cell cytokine 
production[128].  
TAM receptors in NK cells  
 
As previously described, TAM receptors are also expressed by NK cells[116].  
Ligands Gas6 and ProteinS are expressed in bone marrow stromal cells and activate 
TAM receptors on immature NK cells. Interestingly, the expression of TAM receptors is 
necessary for proper NK cell development and functional maturation[116]. In the 
absence of TAM receptor signaling, immature NK cells were unable to acquire 
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expression of inhibitory and activating receptors, which are required for late 
differentiation and effector function[120]. As described above, as part of an elegant 
feedback mechanism, T cells also secrete ProteinS when activated and can therefore 
engage TAM ligand/receptor and subsequently dampen the innate immune response. In 
mature NK cells, TAM receptors attenuate NK cell function. Accordingly, the inhibition of 
TAM receptor signaling prevents metastasis in a mouse tumor model in an NK cell-
dependent manner[75]. The mechanism by which TAMs inhibit NK cell function is not 
known.  
Investigating how Cbl-b and TAM receptors work together to negatively regulate 
NK cells.  
 
Despite the fact that Cbl-b and TAM receptors were found to interact in an in vitro 
proteomics assay[75], the mechanism by which they interact to inhibit NK cell responses 
is unknown. Penninger’s group speculates that Cbl-b negatively regulates NK cells by 
ubiquitinating TAM receptors, which leads to their endocytosis[75]. They further 
speculate that this endocytosed complex is what negatively regulates NK cells. This 
model leaves several unanswered questions. How is Cbl-b activated to ubiquitinate TAM 
receptors? How can an endocytosed complex negatively regulate signaling?  
Given that both Cbl-b and the TAM receptor family are targets for cellular 
immunotherapy, it is critical to understand their biology to better develop targeted 
therapeutics and improve clinical trial outcomes. Therefore, for my thesis work, I wanted 
to determine how TAMs, which as RTKS that are typically associated with enhancement 
of signaling, can inhibit NK cell effector functions. In addition, I was interested in 
understanding what role Cbl-b plays in this negative regulation of NK cell signaling. We 
used recombinant protein and primary NK cells to answer these questions. Lastly, I used 
 
 
27 
Cbl-b KO mice to test several Cbl-b inhibitors in collaboration with Progenra, Inc, to 
assess their efficacy as anti-tumor immunotherapies.  
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CHAPTER 2: TAM receptors attenuate murine NK cell responses via E3 ubiquitin 
ligase Cbl-b 
 
Abstract 
 
TAM receptors (Tyro3, Axl, and Mer) are receptor tyrosine kinases (RTKs) that are 
expressed by multiple immune cells including natural killer (NK) cells. Although RTKs 
typically enhance cellular functions, TAM receptor ligation blocks NK cell activation. The 
mechanisms by which RTKs block NK cell signaling downstream of activating receptors 
are unknown. In this report, we demonstrate that TAM receptors attenuate NK cell 
responses via the activity of E3 ubiquitin ligase Cbl-b. Specifically, we show that Tyro3, 
Axl, and Mer phosphorylate Cbl-b, and Tyro3 ligation activates Cbl-b by phosphorylating 
tyrosine residues 133 and 363. Ligation of TAM receptors by their ligand Gas6 
suppresses activating receptor-stimulated NK cell functions such as IFNγ production and 
degranulation, in a TAM receptor kinase- and Cbl-b-dependent manner. Moreover, Gas6 
ligation induces the degradation of LAT1, a transmembrane adaptor protein required for 
NK cell activating receptor signaling, in WT but not in Cbl-b knock-out NK cells. 
Together, these results suggest that TAM receptors may attenuate NK cell function by 
phosphorylating Cbl-b, which in turn dampens NK cell activation signaling by promoting 
the degradation of LAT1. Our data therefore support a mechanism by which RTKs 
attenuate, rather than stimulate, signaling pathways via the activation of ubiquitin 
ligases.  
Introduction 
 
The TAM receptor family is a group of receptor tyrosine kinases (RTKs) that 
includes Tyro3, Axl, and Mer[77]. TAM receptors have a highly conserved cytoplasmic 
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kinase domain that is activated upon binding with their ligands Gas6 or 
ProteinS[101],[129]. TAM activation leads to their auto-phosphorylation and the 
phosphorylation of tyrosine residues of multiple downstream intracellular signaling 
molecules[77]. In hematopoietic cells, TAM receptors are primarily expressed by cells of 
the innate immune system. 
One important function of TAM receptors is to clear apoptotic bodies. The 
phosphatidyl serine residues of the surface membrane of apoptotic bodies bind to Gas6, 
serving as a means for recognition and subsequent phagocytosis by TAM receptor-
expressing macrophages[121]. Thus, Tyro3, Axl, and Mer triple KO mice display a defect 
in clearing apoptotic bodies, which causes a lupus-like spontaneous autoimmune 
disease[112]. In addition, TAM receptor ligation blocks pro-inflammatory cytokine 
release by macrophages and dendritic cells (DCs)[112],[114],[125].  
In addition to macrophages and DCs, TAM receptors are also expressed by NK 
cells[116]. NK cells are innate lymphocytes that play an important role in killing 
cancerous and virally infected cells by direct cytotoxicity and through the production of 
inflammatory cytokines such as IFNγ[3]. Interestingly, the expression of TAM receptors 
is necessary for proper NK cell development and functional maturation[116]. In mature 
NK cells, TAM receptors attenuate NK cell function. Accordingly, the inhibition of TAM 
receptor signaling prevents metastasis in a mouse tumor model in an NK cell-dependent 
manner[75]. 
RTKs are typically associated with stimulation, rather than inhibition, of activating 
receptor-mediated signaling pathways. For example, ligand binding to epidermal growth 
factor receptor (EGFR) stimulates the ERK, MAPK and AKT pathways, which leads to 
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cell growth and proliferation[130]. However, TAM receptors are unique within the RTK 
family in that they are able to both promote and inhibit signal transduction pathways. 
The mechanism by which TAM receptors inhibit innate immune cells has only 
been well described in DCs, where the TAM receptor Axl is induced upon Toll-like 
receptor (TLR) activation by foreign pathogens. Axl associates with the type I interferon 
receptor, which activates the JAK/STAT pathway and drives the transcription of the 
suppressor of cytokine signaling (SOCS1 and 3) genes[114],[131], which are ubiquitin 
ligases that inhibit cytokine receptor and TLR-mediated signaling. 
Cbl-b, another E3 ubiquitin ligase, was also found to be associated with TAM 
receptors in an in vitro proteomics assay[75]. Cbl-b ubiquitinates TAM receptors, causing 
decreased surface expression, likely through lysosomal degradation[75]. Although this 
interaction appeared to be important for the TAM receptor function in NK cells, the 
mechanism by which TAM receptors attenuate NK cell function is still unclear. 
In this report, we find that while TAM receptors are targets for Cbl-b-mediated 
ubiquitination, Cbl-b is also a phosphorylation target for TAM receptors. Our data 
suggest that TAM receptors may attenuate NK cell function by phosphorylating Cbl-b, 
promoting the degradation of LAT1, a key protein necessary for activating receptor-
mediated signaling in NK cells[68]. 
Results 
Gas6 inhibits IFNγ production and degranulation by WT NK cells stimulated by 
ligation of activating receptors 
We first tested several concentrations of the TAM receptor ligand Gas6 to 
determine which concentration was most effective in inhibiting NK cell activation. A dose 
 
 
31 
range experiment of the effect of Gas6 on the inhibition of NK cell IFNγ production has 
been previously published[75]. In this report, they tested a narrow range of Gas6 
concentrations (0, 200, 400, and 800 ng/ml). We, therefore, tested a wider range of 
Gas6 concentrations in stimulated IL-2-expanded NK cells (Lymphokine Activated Killer 
cells, LAKs) by ligating the activating receptors NK1.1 and NKG2D in the presence or 
absence of Gas6 at either 0, 100, 500, or 2,500 ng/ml, and measured the production of 
IFNγ and cell-surface CD107a expression (a surrogate for degranulation) (Figure 2.1). 
We found that while the concentration of 500 ng/ml led to Gas6-mediated inhibition of 
NK cell responses, the effect was minimal at 100 ng/ml and was even enhanced in some 
instances at a concentration of 2,500 ng/ml. Based on this data and the data that was 
previously published[75], we consistently used a Gas6 concentration of 450 ng/ml for all 
experiments.  
 
 
 
FIGURE 2.1. NK cells are optimally inhibited by Gas6 at 500ng/ml. LAKs were serum and IL-
2-starved for 2 hours, pre-treated with either 0, 100, 500, or 2,500 ng/ml of Gas6 for 2 hours, and 
stimulated with anti-NK1.1 or anti-NKG2D for 5 hours and analyzed by flow cytometry. Cumulative 
data are represented as % of control ± SEM of n=3 mice for anti-NK1.1 and anti-NKG2D. *p< 0.05 
by paired Student t test comparing Gas6 conditions 0 to 500 ng/mL.  
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To examine the effect of TAM receptor-mediated signaling on NK cell activation, 
we stimulated LAKs by ligating the activating receptors NK1.1 and NKG2D in the 
presence or absence of Gas6 and measured the production of IFNγ and cell-surface 
CD107a expression (a surrogate for degranulation). The addition of Gas6 significantly 
decreased the proportion of IFNγ+ and CD107a+ anti-NK1.1- or anti-NKG2D-stimulated 
LAKs (Fig.2.2A-C). To test whether a similar effect was observed in NK cells removed 
freshly ex vivo, NK cells from WT mice pre-treated with the viral mimetic PolyI:C were 
stimulated in the presence or absence of Gas6. Similar to LAKs, a decreased fraction of 
IFNγ+ and CD107a+ NK cells was detected in freshly isolated NK cells treated with Gas6 
and stimulated with anti-NK1.1 (Fig.2.3A-C). These data demonstrate that TAM receptor 
ligation negatively regulates NK cell activation. 
 
 
 
 
 
 
FIGURE 2.2. Gas6 inhibits IFNγ production and degranulation by WT LAKs stimulated 
through activating receptors. LAKs were serum/IL-2-starved for 2 hours, pre-treated with or 
without Gas6 for 2 hours, and left unstimulated (Unstim) or stimulated with PMA/Iono, anti-
NK1.1, or anti-NKG2D for 5 hours and analyzed by flow cytometry. (A) Representative flow 
cytometric plots of IFNγ+ and CD107a+ LAK cells are shown. (B) The fraction of IFNγ-expressing 
and (C) CD107a-expressing LAKs from 4 independent experiments are shown (n = 4 mice for 
anti-NK1.1 and n=5 mice for anti-NKG2D). *p<0.05 and **p<0.01 by paired Student t test.  
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TAM receptor Tyro3 phosphorylates tyrosine residues 133 and 363 of Cbl-b 
 
It has been previously shown that TAM receptors are direct targets of the ubiquitin ligase 
Cbl-b and that these interactions are important for TAM receptors to attenuate NK cell 
function[75]. To further examine the interaction between TAM receptors and Cbl-b, we 
generated recombinant phosphorylated Tyro3 and a truncated Cbl-b composed of the 
tyrosine kinase binding and RING finger domains (TKB+RF). As previously reported[75], 
the addition of Cbl-b to purified Tyro3 induced the ubiquitination of Tyro3 (Fig. 2.4A). 
While Cbl-b typically needs to be pre-activated by Lck-mediated phosphorylation to carry 
out its ubiquitinating function[132], we unexpectedly found that Cbl-b was able to 
ubiquitinate Tyro3 in the absence of Lck. Given that Tyro3 is a kinase, this raised the 
possibility that Tyro3 might be phosphorylating and activating Cbl-b. Indeed, 
FIGURE 2.3. Gas6 inhibits IFNγ production and degranulation by WT NK cells stimulated 
through activating receptors. (A) Splenocytes from Poly I:C-treated mice were pre-treated 
with or without Gas6 for 2 hours and left unstimulated (Unstim) or stimulated with PMA/Iono or 
anti-NK1.1 for 5 hours and analyzed by flow cytometry. Representative flow cytometric plots of 
IFNγ+ and CD107a+ NK cells are shown. The fraction of (B) IFNγ-expressing and (C) CD107a–
expressing splenocytes of 4 independent experiments are shown (n =4-5 mice). *p<0.05 and 
**p<0.01 by paired Student t test.  
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phosphorylated Cbl-b was detected when Cbl-b was mixed with both Tyro3 and ATP 
(Fig. 2.4B). These data suggest that not only was Tyro3 a ubiquitination target of Cbl-b, 
but also that Cbl-b was a phosphorylation target of Tyro3. Furthermore, recombinant Axl 
and Mer also phosphorylate Cbl-b (Fig. 2.4B). 
 
 
 
 
To test whether Cbl-b is phosphorylated upon TAM receptor ligation in NK cells, 
we next examined Cbl-b phosphorylation in LAKs treated with Gas6. Consistent with our 
purified protein assay results, the treatment of LAKs with Gas6 induced the 
phosphorylation of Cbl-b (Fig. 2.5A). To ensure that the phosphorylation was TAM 
kinase-dependent, we pre-treated LAKs with the pan-TAM kinase inhibitor BMS777607 
for 30 minutes prior to stimulation with Gas6; this resulted in the reduction of Cbl-b 
phosphorylation to baseline levels (Fig. 2.5B), suggesting that the induction of Cbl-b 
phosphorylation by Gas6 was TAM kinase-dependent. The ligation of activating 
receptors such as Ly49D and CD16 can also lead to phosphorylation of the Cbl-b 
homologue c-Cbl[133], likely as a feedback mechanism to attenuate NK cell 
overactivation. To test whether Gas6 has a cumulative effect in enhancing Cbl-b 
FIGURE 2.4. Cbl-b ubiquitinates Tyro3, and Tyro3, Axl, and Mer phosphorylate Cbl-b in 
vitro. (A) HA-tagged Tyro3 was incubated with or without truncated Cbl-b (TKB+RF), E1, E2, 
ubiquitin, and ATP in vitro for 1 hour and immunoblotted with anti-HA antibody. (B) Truncated 
Cbl-b (TKB+RF) was incubated with or without recombinant Tyro3, Axl, or Mer and with or 
without ATP in vitro and immunoblotted with anti-phosphotyrosine antibody.  
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phosphorylation with an activating receptor stimulus, we stimulated LAKs with anti-
NK1.1 with or without Gas6. Stimulation of LAKs with anti-NK1.1 antibody PK136 led to 
minimal phosphorylation of Cbl-b, which was synergistically enhanced by Gas6 (Fig. 
2.5B). These data collectively suggest that TAM receptors directly phosphorylate Cbl-b. 
 
 
 
 
 
 
 
Tyrosines 106, 133, and 363 have been previously shown to be required for the 
ligase activity of Cbl-b[48],[49],[132]. Phosphorylation of Tyr363 opens Cbl-b from its 
auto-inhibitory confirmation, allowing E2 and substrates to bind to Cbl-b[48]. To 
determine which of the tyrosines on Cbl-b could potentially be phosphorylated by Tyro3, 
we examined Tyro3-dependent phosphorylation of Cbl-b mutants harboring single Y to F 
mutations at residues Tyr106, Tyr133, and Tyr363, and a triple mutation of all tyrosines 
(Y106/133/363F). Following co-incubation of Y133F, Y363F, and Y106/133/363F 
mutants with Tyro3, we found a decrease in phospho-Cbl-b in comparison to WT Cbl-b 
(Fig. 2.6A). These data suggest that Tyr133 and Tyr363 are the primary tyrosine 
residues that are phosphorylated by Tyro3.    
FIGURE 2.5. TAM receptor activation leads to phosphorylation of Cbl-b in a TAM 
kinase-dependent manner. (A) LAKs were IL-2-starved for 18 hours and serum-starved for 4 
hours followed by stimulation with Gas6 for various time points or (B) followed by stimulation 
with or without Gas6, BMS777607 with Gas6, or anti-NK1.1 (PK136) with or without Gas6 for 
60 minutes. Lysates were de-ubiquitinated with DUB USp2core, followed by 
immunoprecipitation with anti-phosphotyrosine and immunoblotting with anti-Cbl-b antibodies. 
One representative of three independent experiments is shown.  
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To test whether phosphorylation of Cbl-b at Tyr133 and/or Tyr363 by Tyro3 is 
important for its ubiquitin ligase function, we examined the ubiquitination of the Cbl-b 
mutants and Tyro3. Tyr106, Tyr133, and Tyr363 have been previously shown to be 
required for the auto-ubiquitination of Cbl-b[49]. Ubiquitinated Tyro3 and Cbl-b bands 
were detected when Tyro3 was mixed with WT Cbl-b (Fig. 2.6B). These ubiquitination 
bands were slightly decreased in the Y133F mutant and almost undetectable in the 
Y363F and triple mutants. These results show that Tyro3 regulates the function of Cbl-b 
by phosphorylating Tyr363 of Cbl-b. 
 
 
CHAPTER 3 
 
 
TAM receptors attenuate NK cell function by phosphorylating Cbl-b, which 
promotes LAT1 degradation 
Cbl-b negatively regulates NK cell function by ubiquitinating key signaling 
molecules and targeting them for re-localization or degradation[68]. Thus, we 
FIGURE 2.6. TAM receptor Tyro3 phosphorylates tyrosine residues 133 and 363 of Cbl-
b. (A) 10XHis-tagged YàF Cbl-b point mutants were incubated with Tyro3 and ATP, followed 
by immunoblotting with anti-phosphotyrosine antibody. Y3F refers to Y106/133/363F triple 
mutant. (B) 10XHis-tagged YàF Cbl-b point mutants were incubated with Tyro3, E1, E2, 
ubiquitin, and ATP for 1 hour and immunoblotted with anti-ubiquitin antibody. One 
representative of three independent experiments is shown.  
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hypothesized that TAM receptors might inhibit NK cell function by activating Cbl-b 
through its phosphorylation. To test this possibility, we first examined whether the kinase 
activity of TAM receptors was necessary for the suppression of NK cell activation. Cells 
were pretreated with the pan-TAM kinase inhibitor BMS777607 for 2 hours prior to 
stimulation with plate-bound anti-NK1.1 or anti-NKG2D in the presence of Gas6. The 
suppressive effect of Gas6 on LAK IFNγ production and degranulation was partially 
reversed by BMS777607, suggesting that Gas6 may regulate NK cells at least in part by 
the kinase activity of TAM receptors (Fig. 2.7A-B).   
 
 
 
 
 
 
 
Next, we determined whether Cbl-b was functionally required for TAMs to inhibit 
NK cells. Cbl-b KO and WT LAKs were stimulated with plate-bound anti-NK1.1 or anti-
NKG2D antibodies in the presence or absence of Gas6, and the supernatants were 
FIGURE 2.7. TAM receptors attenuate NK cell function via their kinase activity. LAKs were 
treated with media (0.05% DMSO) or BMS777607 (100 nM) for 2 hours in IL-2/serum-free 
conditions, followed by treatment with or without Gas6 for another 2 hours prior to stimulation with 
anti-NK1.1 or NKG2D for 5 hours. Cells were stained for IFNγ and CD107a expression and 
analyzed by flow cytometry. (A) The IFNγ+ and CD107a+ LAK cells are depicted for all conditions. 
1 representative experiment of 4 independent experiments is shown. (B) Cumulative data is shown 
as mean % inhibition {(Untreated - Gas6-treated)/Untreated]*100} ± SEM of 4 independent 
experiments (n = 4-5 mice for anti-NK1.1 and n=5-6 mice for anti-NKG2D). *p<0.05 as determined 
by paired Student t test.  
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assayed for IFNγ by ELISA at 24 hours. Consistent with our flow cytometric data, the 
addition of Gas6 to WT LAKs significantly inhibited IFNγ release. However, Gas6 
treatment displayed no inhibitory effect towards anti-NK1.1 or anti-NKG2D-stimulated 
Cbl-b KO LAKs (Fig.2.8A-B). In fact, Cbl-b KO LAKs have enhanced IFNγ release 
compared to WT LAKs (Fig.2.8A), consistent with previously published studies[75]. 
Together, these data suggest that the phosphorylation of Cbl-b is required for the 
Gas6/TAM pathway to inhibit pro-inflammatory cytokine production by NK cells. 
 
 
 
 
To gain insight into how the TAM/Cbl-b pathway may be regulating NK cell 
signaling, we assessed degradation of PLCγ1, the p85 subunit of PI3K, and LAT1- key 
signaling molecules downstream of NK cell activating receptors and known targets for 
ubiquitination and degradation by Cbl-b[68]. Upon Gas6 ligation, only LAT1 levels were 
FIGURE 2.8. Cbl-b is required for TAM receptors to attenuate NK cell function. WT and 
Cbl-b KO LAKs were serum/IL-2-starved for 2 hours, followed by Gas6 treatment for 2 hours, 
and stimulated with anti-NK1.1 or anti-NKG2D antibodies for 24 hours. IFNγ content in the 
supernatants was measured by ELISA. (A) Representative data for 1 experiment. (B) 
Cumulative data are represented as % of control ± SEM of n=4 mice for anti-NK1.1 and n=3 
mice for anti-NKG2D. *p< 0.05 and ***p <0.001 by paired Student t test. ns, not significant.  
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decreased over time in WT LAKs (Fig. 2.9A), whereas Cbl-b KO LAKs were unaffected 
(Fig. 2.9B). 
 
 
 
 
 
 
 
Lastly, we asked whether TAM/Cbl-b activation is followed by a negative 
feedback response, which would allow the NK cell to return to baseline and respond to a 
cancerous or virally-infected cell. We hypothesized that in order for this to occur, Cbl-b 
would need to be degraded. To test whether Cbl-b is degraded after TAM receptor 
ligation in NK cells, we next examined total levels of Cbl-b in LAKs treated with Gas6. 
The treatment of LAKs with Gas6 led to a decrease in total Cbl-b (Fig. 2.10A). To 
ensure that Cbl-b was being proteolytically degraded, we pre-treated LAKs with MG132 
(proteasome inhibitor) and chloroquine (lysosome inhibitor); however, these pre-
treatments were toxic to the cells (Fig. 2.10B).  
FIGURE 2.9. TAM receptors attenuate NK cell function by phosphorylating Cbl-b, 
which promotes LAT1 degradation. (A) LAKs were serum and IL-2-starved for 4 
hours followed by Gas6 stimulation for various time points. Cell lysates were 
immunoblotted with anti-PLCγ1, anti-p85, anti-LAT1, and β-actin antibodies. (B) LAKs 
from WT and Cbl-b KO mice were serum and IL-2 starved for 4 hours followed by Gas6 
stimulation for various time points. Cell lysates were immunoblotted with anti-LAT1 and 
β-actin antibodies. The relative ratio of LAT1 to β-actin for each time point, normalized 
to the 0 time-point for each genotype, is shown below the blots. One representative of 
three independent experiments is shown. 
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Together, these data support a novel mechanism whereby TAM receptors 
negatively regulate NK cell function by phosphorylating Tyr363 of Cbl-b, which in turn 
dampens NK cell activation signaling by promoting the degradation of positive signaling 
molecules such as LAT1. This attenuation in signaling may then negatively signal back 
to Cbl-b, which in turn is degraded, allowing NK cells to reset (Fig. 2.11). 
FIGURE 2.10 Cbl-b may be degraded after Gas6/TAM stimulation. (A) LAKs were serum and 
IL-2-starved for 4 hours followed by Gas6 stimulation for various time points. Cell lysates were 
immunoblotted with anti-Cbl-b and β-actin antibodies. (B) LAKs were serum and IL-2-starved for 
4 hours and left either untreated or treated with MG132 and chloroquine followed by Gas6 
stimulation for various time points. The relative ratio of Cbl-b to β-actin for each time point is 
shown below the blots. One representative of three independent experiments is shown. 
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Discussion 
Previously published data showed that Gas6 inhibited NK cell responses but the 
range of Gas6 concentration was narrow (200, 400, and 600 ng/mL)[75]. We found that 
while the concentration of 500 ng/ml led to Gas6-mediated inhibition of NK cell 
responses, the effect was minimal at 100 ng/ml and was even enhanced in some 
instances at a concentration of 2,500 ng/ml. The enhancement of NK cell responses 
may be due to enhanced survival of NK cells treated with high concentrations of Gas6, 
as Gas6 has an effect on cell survival and proliferation. Because this experiment is done 
under serum-starved conditions, NK cells treated with higher concentrations of Gas6 
may survive better than cells treated with a lower concentration of Gas6.  
FIGURE 2.11 Gas6/TAM signaling inhibits NK cell activation through Cbl-b. Gas6 binds and 
activates TAM receptors, which directly phosphorylates Cbl-b. Phosphorylated Cbl-b, in turn, 
ubiquitinates and targets LAT1 for degradation. NK1.1/NKG2D signaling is attenuated by 
decreased LAT1 protein, which is required for signal transduction downstream of NK cell 
activating receptors. Lastly, this signaling attenuation may lead to the degradation of Cbl-b as a 
form of negative feedback regulation.  
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In addition, the percent of Gas6-mediated inhibition does not appear to be 
substantial with an average of about 30% reduction of IFNy and CD107a. However, in 
comparison to the previously published work where reduction was about 15%. This 15% 
reduction was enough to produce a biological response. Therefore, although the in vitro 
experiment data does not seem substantial, based on the previously published work, this 
is enough to create a biological response.  In order to address the seemingly inadequate 
Gas6-mediated reduction in IFNy and CD107a, we used alternative approaches, such as 
ProteinS instead of Gas6. ProteinS, however, did not reduce IFNy and CD107a. It is well 
documented that the best inhibition of TAM receptors occurs when Gas6 is bound to 
phosphatidylserine[105]. Therefore, we prepared liposomes consisting of 
phosphatidylserine with Gas6 or Protein. Our control of PS liposome alone led to 
reduction in IFNy and CD107a. Human NK cells express an inhibitory receptor, CD300, 
which binds to PS[134-136]. Therefore, the effect we saw with PS alone may be due to 
direct inhibition through a similar receptor in murine NK cells.   
The in vitro biochemical data shown in Figure 2.4B was variable. Tyro3 
phosphorylated large quantities of Cbl-b. Although Axl and Mer also phosphorylated Cbl-
b, the amount of phosphorylation is not equivalent to that phosphorylated by Tyro3. The 
recombinant proteins were derived from different sources, and thus, are likely of varying 
quality. In addition, we did not test for whole amounts of recombinant protein being 
added into the assay. Therefore, each experiment may have different amounts of kinase, 
and thus, lead to differing amounts of phosphorylated Cbl-b.  
We showed that ligation of TAM receptors leads to phosphorylation of Cbl-b. The 
ligation of activating receptors such as Ly49D and CD16 can also lead to 
phosphorylation of Cbl-b homologue c-Cbl[133],[137], likely as a feedback mechanism to 
 
 
43 
attenuate NK cell overactivation. Our data showed that Gas6 has a cumulate effect in 
enhancing Cbl-b phosphorylation with co-incubation of an activating receptor stimulus 
NK1.1 and Gas6. TAM ligation with Gas6 and anti-NK1.1 stimulus may separately lead 
to the phosphorylation of Cbl-b and appear to be synergistic. Although the 
phosphorylation of Cbl-b via the ligation of NK1.1 and TAM receptors may be 
synergistic, they are likely independently leading to the phosphorylation of Cbl-b. In 
addition, it is unknown which tyrosine(s) is/are phosphorylated by each agent, and, 
therefore, the mechanism and sites of phosphorylation can be different.   
TAM receptors are RTKs that inhibit the pro-inflammatory function of a variety of 
cell types. While it has been shown that TAM receptors attenuate DC function through 
the transcriptional induction of SOCS proteins[114], the mechanism by which TAM 
receptors attenuate activating receptor-stimulated NK cell function is unknown. In this 
report, we provide data that supports a mechanism by which TAM receptors attenuate 
pro-inflammatory responses via post-translational modification of the E3 ubiquitin ligase 
Cbl-b. By activating Cbl-b through its phosphorylation, TAM receptor ligation can inhibit 
NK cell function potentially by inducing the degradation of key molecules necessary for 
activating receptor signaling, such as LAT1. 
RTKs are typically associated with stimulation rather than inhibition of activating 
receptor-mediated signaling pathways[130]. Accordingly, the tyrosine kinase activity of 
TAM receptors activates ERK, AKT, and NFκB – key signaling pathways required for NK 
cell cytokine production[77]. Thus, it is puzzling that TAM receptors attenuate, rather 
than augment, NK cell function. Our data reveal a mechanism by which RTKs inhibit 
activating receptor stimulation in NK cells. Namely, by phosphorylating and activating 
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Cbl-b, TAM receptors can selectively suppress signaling through activating receptors by 
targeting LAT1 for degradation. 
Cbl-b has been shown to negatively regulate T cells, macrophages, and more 
recently NK cells[138]. In T cells, Cbl-b has been shown to ubiquitinate not only the T 
cell receptor, but also downstream signaling molecules such as p85, PLCγ, and PLCθ – 
which are all required for T cell effector function[139]. In NK cells, Cbl-b has also been 
shown to ubiquitinate key signaling molecules including the transmembrane adaptor 
protein LAT1[68]; LAT1 is part of the multi-molecular signaling complex that forms 
downstream of activating receptors and is required for signaling and cytolytic 
activity[140],[141].   
Along with LAT1, we also assessed the stability of other key signaling molecules 
such as PLCγ1 and the p85 subunit of PI3K after Gas6 stimulation. Although only LAT1 
was degraded after 60 minutes of Gas6 stimulation, lack of degradation of these proteins 
does not preclude them from being involved in TAM/Cbl-b-mediated inhibition of NK cell 
activation. Ubiquitination can also affect localization of the protein within the cell, block 
posttranslational modifications, or can even alter binding to other proteins[40],[43]. 
Therefore, although these proteins are not degraded upon Gas6 stimulation, Cbl-b may 
still be regulating NK cell responses by changing their localization. In addition, although 
our results show that Gas6-mediated LAT1 degradation is mainly controlled by Cbl-b, 
other additional ubiquitin ligases can be involved LAT1 degradation.  
Pathways, whether activating or inhibitory, require a regulatory mechanism to 
allow cells to return to baseline signaling and respond to acute changes in their 
environment. Cbl-b is known to self-regulate via auto-ubiquitination and degradation[46]. 
 
 
45 
We, therefore, assessed the stability of Cbl-b with longer stimulation by Gas6. Total 
levels of Cbl-b were in fact reduced by 120 minutes. However, we were unable to verify 
that it was proteolytically degraded because pre-treatment with MG132 and chloroquine 
were toxic for the cells as shown by decreased levels of β-actin.  
Our investigation was initially prompted by a previous report showing that TAM 
receptors are ubiquitinated by Cbl-b[75]. In this study, Gas6 treatment of NK cells led to 
a decrease in surface expression of TAM receptors in a Cbl-b-dependent manner. This 
ubiquitin-dependent endocytosis of TAM receptors was proposed to be necessary for the 
induction of its inhibitory signal transduction pathway. Consistent with these data, we 
also found that Tyro3 is ubiquitinated by Cbl-b. However, while it is possible that Cbl-b-
mediated endocytosis of TAM receptors is critical for the inhibitory function of TAM 
receptors, it remained unclear as to how this endocytosis could subsequently inhibit NK 
cell functions. Instead, our data favor a model in which the inhibitory function of TAM 
receptors is carried out by Cbl-b-mediated ubiquitination of activating receptor-
associated signaling molecules. In this model, the downregulation of TAM receptors by 
Cbl-b-mediated ubiquitination could play a role in feedback attenuation of TAM receptor 
signaling. In support of this type of negative feedback, another RTK, epidermal growth 
factor receptor (EGFR), has been shown to be ubiquitinated by a homolog of Cbl-b, c-
Cbl[142]. 
Despite differences in the molecules involved, there are similar mechanisms by 
which TAM receptors inhibit cytokine production in DCs; in these cells, Axl ligation up-
regulates the transcription of the ubiquitin ligases SOCS1 and SOCS3, which block TLR-
mediated (MyD88 and TRIF) and cytokine-mediated (JAK/STAT) signaling[114]. While 
the increased expression of SOCS1 and SOCS3 does not affect activating receptor-
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mediated activation in NK cells, TAM receptors post-transcriptionally activate Cbl-b, 
which downregulates components of activating receptor-mediated but not TLR- or 
cytokine-mediated signaling. Thus, TAM receptors may (through two independent 
mechanisms) induce ubiquitin ligase-mediated attenuation of signaling through TLRs, 
cytokines, and activating receptors, to provide broad control of signaling pathways in 
innate cells of the immune system.  
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CHAPTER 3: Enhancing NK cell responses by pharmacological inhibition of Cbl-b  
 
Introduction 
 
NK cells represent a promising target for treatment of tumors and chronic 
infections. Although the effector function of NK cells overlaps with CD8+ T cells, they 
respond to different stimuli and complement the activity of CD8+ T cells, especially in 
settings where CD8+ T cell responses are no longer effective. However, NK cell 
responses alone are often suboptimal to control tumor growth or viral infections. In 
addition, NK cells rapidly adjust to their environment and can display signs of exhaustion 
after chronic activation, making it difficult to sustain their effector function. Thus, 
strategies that involve the enhancement of NK cell activity are necessary to fully harness 
their therapeutic potential. Manipulation of signaling pathways is an attractive approach, 
but the research thus far is limited to mouse models and in vitro human NK cell 
activation assays. Most of the strategies currently being tested at the bedside involve the 
manipulation of cell surface receptors and cytokines to enhance the activity of NK cells 
in neoplastic settings. Although none of the strategies are yet fully optimized and 
effective, the development of novel inhibitors of signaling pathways (e.g. Cbl) and the 
clever combination of cytokines and receptor/ligand pairs will likely improve the 
effectiveness of NK cell-based immunotherapies.   
Cbl-b has also been shown to be a promising immunotherapy target in various 
disease models. The enhanced T cell effector functions in the absence of Cbl-b 
prompted scientists to determine whether Cbl-b regulates anti-tumor responses. Indeed, 
genetic deletion of Cbl-b conferred spontaneous in vivo rejection of tumor cells 
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expressing human papilloma virus antigens[60]. In addition, ablation of Cbl-b in the 
tumor-prone ataxia telangiectasia mutated (ATM)-deficient mice reduced the incidence 
of spontaneous thymic lymphomas[139]. Mice lacking Cbl-b also develop significantly 
fewer ultraviolet B (UVB)-induced skin malignancies and reject UVB-induced skin 
tumors[60]. These mice also reject transplanted E.G7 and EL4 lymphomas[139]. This 
rejection in the absence of Cbl-b was found to be due to activated CD8+ T cells, which 
are resistant to regulation by regulatory T cells or TGF- β[60,139]. In fact, the adoptive 
transfer of CD8+T cells lacking Cbl-b improved survival of murine models of 
leukemia[140].  
Mice harboring a Cbl-b E3 ligase-defective mutation (C373A) are resistant to the 
development of tumors in vivo and rejected tumors in both experimental and 
spontaneous tumor models[60,73,139]. This suggested that Cbl-b was negatively 
regulating immune cell function through its ubiquitin ligase domain[73]. 
Cbl-b was originally considered a regulator of TCR-induced T cell activation[36], 
but in another study, Cbl-b KO mice were found to spontaneously reject tumors even on 
a recombination-activating gene 2 (RAG2) KO background[75]. This effect was lost 
when NK cells were depleted, suggesting that Cbl-b KO NK cells also display enhanced 
anti-tumor activity[75]. In addition, metastatic tumor burden was significantly reduced 
when NK cells from Cbl-b KO and Cbl-b ligase mutant (C373AKI/KI) mice were adoptively 
transferred to a NeuT metastatic breast cancer model. Together, these data suggest that 
Cbl-b negatively regulates NK cell function through the ubiquitin ligase domain[75]. 
Therapies to inhibit Cbl-b have been evaluated in murine models of disseminated 
candidiasis[141] where Cbl-b is targeted using gene silencing via siRNA or a small 
inhibitory peptide[142], both in a macrophage-dependent manner. Peptide-based 
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inhibition of Cbl-b increased cellular responses to fungal stimulation in vitro and 
protected mice from sepsis after systemic infection with C. albicans. To date, there has 
been one small phase 1 clinical trial in 3 patients to assess the inhibition of Cbl-b in 
humans[143]. APN401 is an autologous peripheral blood mononuclear cells (PBMCs) 
suspension that is transfected with an siRNA that knocks down Cbl-b. This suspension 
was tested in human patients suffering from metastatic solid tumors. CD56 cells were 
most efficiently transfected (55%), followed by CD3 (46%), CD19 (45%), and CD14 
(23%) cells. Cbl-b-siRNA-transfected PBMCs produced more IFNγ and IL-2 in response 
to stimulation with anti-CD3 and anti-CD28 antibodies in vitro. In patients, the APN401 
infusions were well tolerated with no resulting autoimmune adverse effects. These 
results showed that Cbl-b can be safely targeted in humans.  
Although the therapeutic efficacy of inhibiting Cbl-b in humans has yet to be 
shown to be dependent on T cells and NK cells, murine Cbl-b KO T cells and NK cells 
have enhanced effector functions, including cytokine production and direct tumor killing- 
making them potential targets to enhance antitumor and antiviral responses.  
Cbl-b makes for an excellent immune checkpoint target because of its dual role 
in T cells and NK cells. Even though APN401 shows promise in a phase 1 clinical trial, 
establishing a therapeutic paradigm consisting of removing a patient’s PBMCs, followed 
by transfection with Cbl-b siRNA, and re-infusion back into a patient is costly, time-
consuming, and inefficient as electroporation does not guarantee siRNA is being 
introduced into each cell. More importantly, there are further risks of developing other 
cancers with this therapy as viral transduction can introduce new mutations into cells. 
Instead, small molecule inhibition of Cbl-b provides a safer alternative. In addition, small 
molecule inhibitors would make the therapy transient and reversible: two qualities sought 
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after for immune checkpoint blockade to prevent autoimmunity. Therefore, we set out to 
test several small molecule inhibitors of Cbl-b developed by Progenra, Inc.  
Results  
 
Small molecule #52642 inhibits Cbl-b mediated Tyro3 ubiquitylation in a dose-
dependent manner  
A small molecule is a low molecular weight organic compound of approximately 1 
nm in size that may regulate a biological process[144]. Small molecules can be designed 
to inhibit certain domains or groups of domains in a protein, preventing its enzymatic 
function or its binding to other proteins.  These compounds are usually ≤500Da size and 
are often administered orally. Their small size also allows them to translocate through 
the plasma membrane and interact with the cytoplasmic domain of cell-surface receptors 
and intracellular signaling molecules. In principle, small molecule compounds can be 
developed to target any portion of a molecule, regardless of the target protein’s location 
inside the cell[144].  
A small molecule inhibitor of Cbl-b can be designed to inhibit Cbl-b in many 
ways. Ideally, since Cbl-b is an E3 ubiquitin ligase, a small molecule should be designed 
to inhibit Cbl-b’s ligase activity. This can be accomplished in several ways. A small 
molecule can be designed to bind to the TKB domain, preventing substrates from 
binding to Cbl-b. It can also be designed to bind the linker region, covering essential 
tyrosines and preventing phosphorylation and thus the activation of Cbl-b. In 
collaboration with Progenra, Inc., we tested dozens of small molecule inhibitors they 
developed using a high throughput screening approach. Progenra, Inc. developed the 
UbiPro™ Drug Discovery Platform (https://progenra.com/therapeutic-focus/rd-platform/) 
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to screen a diverse collection of >600,000 drug-like small molecules where they then 
develop selected hits into therapeutic candidate molecules. The platform is divided into 3 
categories: functional, biophysical, and cellular validation.  The functional screen 
includes TR-FRET (Time Resolved Fluorescence Resonance Energy Transfer) assay to 
demonstrate ubiquitination in real time and an AlphaScreen™ ubiquitination assay to 
achieve higher sensitivity by measuring the proximity of biotinylated ubiquitin (b-Ub) and 
GST-tagged substrate proteins[145].  This step is followed by biophysical assays, such 
as surface plasmon resonance (SPR), which uses light refraction of unlabeled substrate 
bound to glass, to ensure binding of the molecule to a target substrate. Differential 
scanning fluorimetry, which uses thermal shifts, is then used to identify compounds that 
are thermally stabilized. These functional and biophysical assays are then followed by 
cellular assays for validation.  
Jurkat T cells, an immortalized human T cell line, were used for the cellular 
screen of compounds. Jurkat cells were treated with the compounds, their supernatant 
was collected, and IL-2 production was measured as a readout for T cell activation. A 
screen revealed a family of compounds labeled #P0052 that inhibited IL-2 secretion in 
Jurkat cells (data not shown). Next, these compounds were tested biochemically for their 
ability to specifically block Cbl-b’s E3 ubiquitin ligase activity. In a proteomics screen, 
TAM receptor Tyro3 was shown to be a target substrate of Cbl-b[75]. This data was 
validated in HEK 293T cells transfected with V5-Tyro3, FLAG-WT Cbl-b or FLAG-ligase 
mutant Cbl-b, and HA-ubiquitin. WT Cbl-b ubiquitinated Tyro3 in 293T cells while ligase 
mutant Cbl-b had a decreased ability to ubiquitinate Tyro3, validating that Cbl-b targets 
Tyro3 for ubiquitination (Fig. 3.1A-B).  
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Each compound that blocked Jurkat IL-2 production was then incubated in a cell-
free ubiquitination reaction with Cbl-b and Tyro3.  Several compounds of family #P0052 
were shown to inhibit ubiquitination of Tyro3 when compared to control DMSO (Fig. 
3.2A). To show that this compound specifically inhibits E3 and not E1 or E2 proteins, the 
compounds were incubated at varying concentrations with E1 and E2 in a ubiquitination 
reaction. No inhibition in the interaction between E1 or E2 and ubiquitin was detected 
with incubation with compound #52642, similar to reactions in DMSO (Fig. 3.2B). The 
IC50, or the concentration of an inhibitor where the response is reduced by half, was 
determined using ubiquitination of Tyro3 as a surrogate for Cbl-b activity. Two varying 
lengths of Cbl-b recombinant protein were used: full length and a truncated version with 
only the TKB and RF domains. Ubiquitination of Tyro3 was reduced by 50% with 4.6 μM 
of inhibitor #52642 (Fig. 3.2C).  The IC50s using either full length or truncated Cbl-b 
FIGURE 3.1 Ligase mutant Cbl-b has a decreased ability to ubiquitinate Tyro3 in cells. 
HEK 293T cells were transfected with V5-Tyro3, HA-Ubiquitin, and either FLAG-tagged WT or 
ligase mutant Cbl-b C373A, followed by immunoprecipitation with V5 and immunoblotting with 
HA, FLAG, and V5. (A) Cells transfected with FLAG-WT Cbl-b had enhanced ubiquitination of 
Tyro3 compared to cells transduced with ligase mutant Cbl-b. (B) Tyro3 ubiquitination was 
quantified using Image J analysis.  
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were similar. These results suggest that the #52642 family of compounds are specific 
inhibitors of E3 ligase activity.  
 
 
 
 
 
 
 
WT and Cbl-b KO NK cells are appropriate cellular models to test for inhibitor 
efficacy and specificity    
We set out to establish a model where we could test the Cbl-b inhibitors to 
assess their toxicity, ability to enhance T and NK cell effector functions, and specificity to 
Cbl-b. LAKs prepared from WT and Cbl-b KO mice were stimulated with antibodies that 
target several different activating receptors: NK1.1, NKG2D, 2B4, or Ly49D. NK1.1 and 
FIGURE 3.2 Small molecule #52642 inhibits Cbl-b mediated Tyro3 ubiquitylation in a 
dose-dependent manner. (A) Compounds generated by Progenra’s UbiPro™ Drug 
Discovery Platform were incubated with E1, E2, HA-Tyro3, and GST-Cbl-b, followed by 
immunoblotting with anti-HA. All compounds tested inhibited ubiquitination of Tyro3 
compared to control. (B) E1 and E2 were incubated with different concentrations of inhibitor 
#52642 followed by immunoblotting with anti-ubiquitin. The ubiquitination status of E1 and 
E2 incubated with #52642 were comparable to E1 and E2 treated with DMSO. (C) IC50 was 
determined by incubating full length Cbl-b, truncated Cbl-b (TKB+RING domains), or DMSO 
with Tyro3, E1, and E2. Ubiquitination was detected by streptavidin-HRP luminescence. 
Small molecule #52642 inhibited the E3 ligase function of both full length and truncated 
forms of Cbl-b, and ubiquitination of half of the Tyro3 molecules (IC50) was inhibited at a 
concentration of 4.6μM.  
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Ly49D use ITAM-mediated adaptor molecules for signal transduction, whereas NKG2D 
and 2B4 use YxxM motif-containing costimulatory adaptors and SAP, respectively, to 
transduce their signals. The cells were gated on NK cells and assessed for IFNγ and 
CD107a (surrogate for degranulation). LAKs deficient in Cbl-b had significantly 
increased IFNγ+ and CD107a+ production under stimulation with anti-NK1.1 or anti-
NKG2D (Fig. 3.3A-C).  These data are consistent with previous findings that NK cells 
deficient in Cbl-b are hyperactivated[75].      
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To test whether a similar effect was observed in NK cells removed freshly ex 
vivo, NK cells from WT and KO Cbl-b mice were stimulated with antibodies targeting 
activating receptors. Similar to LAKs, an increased fraction of IFNγ+ and CD107a+ NK 
cells was detected in freshly isolated splenocytes stimulated with anti-NK1.1, anti-
NKG2D, and anti-2B4 (Fig 3.4A-C).  
FIGURE 3.3. Cbl-b KO LAKs have enhanced IFNγ production and degranulation. IL-2 
expanded NK cells (LAKs) were cultured from NK cells isolated from WT or Cbl-b KO mice. LAKs 
were serum- and IL-2-starved and left unstimulated (Unstim) or stimulated with PMA/Iono, anti-
NKG2D, anti-NK1.1, anti-2B4, or anti-Ly49D for 5 hours. (A) Representative flow cytometric plots 
of LAK IFNγ and CD107a expression is shown (gated on CD4-CD8-NK1.1+ or CD4-CD8-NKG2D+ 
LAKS). B) The fraction of IFNγ-expressing and (C) CD107a–expressing LAKs is represented as 
mean ± SEM of 3 independent experiments (n = 3 mice per genotype per condition). *p<0.05, 
**p<0.01, ***p <0.001 by paired Student t test; ns, not significant.  
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FIGURE 3.4 Cbl-b KO NK cells have enhanced IFNγ production and degranulation. 
Splenoctyes from WT and Cbl-b KO mice were left unstimulated (Unstim) or stimulated with 
PMA/ Iono, anti-NKG2D, anti-NK1.1, anti-2B4, or anti-Ly49D for 6 hours. (A) Representative flow 
cytometric plots of NK cell IFNγ and CD107a expression are shown (gated on CD3-
DX5+NKp46+). The fraction of (B) IFNγ-expressing and (C) CD107a–expressing splenocytes is 
represented as mean ± SEM of 3 independent experiments (n =3 mice per genotype per 
condition). *p<0.05 and **p<0.01 by paired Student t test, respectively; ns, not significant.  
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To test if Cbl-b is negatively regulating NK cells in a physiological setting, NK 
cells from WT and KO Cbl-b mice pre-treated with the viral mimetic PolyI:C were 
stimulated by antibodies targeting activating receptors. Similar to LAKs and fresh NK 
cells, an increased fraction of IFNγ+ and CD107a+ NK cells was detected in PolyI:C 
treated splenocytes stimulated with anti-NK1.1, anti-NKG2D, and anti-2B4 (Fig 3.5A-C).  
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Cbl-b KO NK cells are phenotypically normal  
To ensure that there were no phenotypic differences between WT and Cbl-b KO 
NK cells, fresh NK cells were isolated from the splenocytes of WT or Cbl-b KO mice and 
analyzed for cell number, cell surface receptor repertoire, and maturation state by flow 
cytometry. Cell number was analyzed as percent splenic NK cells and no difference in 
cell number was observed between WT and Cbl-b KO NK cells (Fig. 3.6A).  
FIGURE 3.5 PolyI:C treated Cbl-b KO NK cells have enhanced IFNγ production and 
degranulation. Splenoctyes from Poly I:C-treated mice were left unstimulated (Unstim) or 
stimulated with PMA/ Iono, anti-NKG2D, anti-NK1.1, or anti-2B4 for 5 hours. Representative flow 
cytometric plots of NK cell (A) IFNγ and (B) CD107a expression are shown (gated on CD3-
DX5+NKp46+). One representative of two independent experiments is shown.  
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The cell surface receptors analyzed are part of the Ly49 family of receptors on 
murine NK cells, which play a key role in NK cell function. Ly49 receptors Ly49A, Ly49G, 
Ly49C, and Ly49I are inhibitory receptors, whereas Ly49D and Ly49H are activating 
receptors[10]. This receptor family is used to phenotype NK cells because Ly49 
receptors are acquired in a sequential and variegated manner during development, 
which yields a diverse repertoire of NK cells with various Ly49 receptor expression 
patterns[10]. Since each Ly49 receptor recognizes a subset of MHC I alleles, the Ly49 
receptor expression pattern on an individual NK cell determines its target cell specificity. 
Ly49 receptor genes are activated in a specific order, and each receptor possesses a 
developmental time frame for the initiation of expression, which is maintained for the 
lifetime of the NK cell. Splenocytes from WT, Cbl-b heterozygous, or Cbl-b knockout 
mice were phenotyped for these Ly49 receptors by flow cytometry and there were no 
differences found in Ly49 receptor expression (Fig. 3.6B).  
The maturation of NK cells is a 4-step developmental program, which is 
associated with a progressive acquisition of receptors and NK-cell effector 
functions[146]. Surface density of CD27 and CD11b subdivides murine NK cells into 4 
subsets: CD11b(low)CD27(low), CD11b(low)CD27(high), CD11b(high)CD27(high), and 
CD11b(high)CD27(low). CD11b(low)CD27(low) NK cells are the most immature, 
whereas CD11b(high)CD27(low) NK cells are fully matured with effector functions that 
include cytokine production and degranulation[146]. Splenocytes from WT and Cbl-b KO 
mice were stained for CD11b and CD27 and gated on NK cells. There were no 
significant differences in maturation state between WT and Cbl-b KO NK cells (Fig. 
3.6C).  These studies informed us that the Cbl-b KO mouse model was an adequate 
model in which to study the safety and efficacy of Cbl-b inhibitors.  
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APPENDIX (OPTIONAL) 
52642 enhances NK and T cell effector functions but is not specific for Cbl-b 
Cbl-b inhibitors were first tested on WT NK cells to assess for their ability to 
enhance cytokine production and degranulation. WT NK cells were pre-treated with 
either inhibitor or DMSO followed by stimulation with anti-NK1.1 or ati-NKG2D. 
Splenocytes were then analyzed by flow cytometry, gated on live NK cells and analyzed 
for IFNγ and CD107a. Although there was no enhancement of IFNγ when stimulated 
with anti-NKG2D, there was an enhancement of IFNγ with anti-NK1.1 stimulation and an 
FIGURE 3.6 Cbl-b KO NK cells are phenotypically normal. (A) Cell number was analyzed as 
percent splenic NK cells and no difference in cell number was observed between WT and Cbl-b KO 
NK cells. (B) Splenocytes from WT, Cbl-b heterozygous, or Cbl-b knockout mice were phenotyped for 
Ly49 receptors by flow cytometry and there were no differences found in Ly49 receptor expression 
between the WT, Cbl-b HET, or Cbl-b KO NK cells. (C) Splenocytes from WT and Cbl-b KO mice 
were stained for CD11b and CD27 and gated on NK cells. There were no significant differences in 
maturation state between WT and Cbl-b KO NK cells. The data is represented as mean ± SEM of 3 
independent experiments (n =3 mice per genotype per condition). *p<0.05 and **p<0.01 by paired 
Student t test, respectively; ns, not significant.  
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increase in CD107a expression with activation of both receptors when treated with 
inhibitor #52642 when compared to DMSO (Fig. 3.7).  
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FIGURE 3.7 NK cells treated with compound #52642 have enhanced degranulation and IFNγ 
production. Splenoctyes from WT mice were pre-treated with DMSO or putative Cbl-b inhibitors 
(10μm), left unstimulated (Unstim) or stimulated with PMA/ Iono, anti-NKG2D, anti-NK1.1, or anti-
2B4 for 6 hours.  Representative flow cytometric plots of NK cell (A) IFNγ and (B) CD107a 
expression are shown (gated on CD3-DX5+NKp46+). (C-D) Cumulative data is shown as mean % 
enhancement {(DMSO - 52642-treated)/DMSO]*100} ± SEM of 4 independent experiments (n = 4-5). 
*p< 0.05 and ***p <0.001 by paired Student t test, respectively.  
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To test whether the Cbl-b inhibitor was specific for Cbl-b or whether it may also 
target c-Cbl, Cbl-b KO NK cells were pre-treated with either inhibitor or DMSO followed 
by stimulation with antibodies targeting activating receptors NK1.1 or NKG2D. 
Splenocytes were then analyzed by flow cytometry, gated on NK cells, and analyzed for 
IFNγ and CD107. Treatment of Cbl-b KO NK cells with inhibitor #52642 led to their 
enhanced degranulation and IFNγ when compared to WT NK cells, suggesting that 
inhibitor #52642 was not specific for Cbl-b (Fig. 3.8).  
 
 
 
 
 
FIGURE 3.8 Putative Cbl-b inhibitor #52642 also enhances Cbl-b KO NK cells. 
Splenoctyes from Cbl-b KO mice were pretreated with DMSO or compound #52642 (10 
μM) and left unstimulated (Unstim) or stimulated with PMA/ Iono, anti-NKG2D, or anti-
NK1.1 for 6 hours. Representative flow cytometric plots of NK cell IFNγ and CD107a 
expression are shown (gated on CD3-DX5+NKp46+). Putative Cbl-b inhibitor 52642 
enhanced both IFNγ and CD107a compared to DMSO controls. One representative of two 
independent experiments is shown.  
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Cbl-b is also expressed in T cells and has been shown to be a key regulator of 
threshold activation. CD8+T cells lacking Cbl-b have been shown to have enhanced anti-
tumor activity, and thus is another cellular target cell for Cbl-b inhibition. We therefore 
sought out to assess the effect of the inhibitors on T cells. CD8+ T cells isolated from WT 
mice were grown in culture, labeled with CFSE, treated with DMSO or Cbl-b inhibitor 
#52642, and assessed for proliferation after 24 hours. Putative Cbl-b inhibitor #52642 
enhanced proliferation of CD8+ T cells compared to DMSO control (Fig. 3.9A). To 
assess for effector functions, WT CD4+ and CD8+ T cells were pre-treated with the 
inhibitor #52642 and another set of compounds (#87678, 87793, and 87798), stimulated 
with anti-CD3, and their supernatant assayed for IL-2 production. Both CD4+ and CD8+ 
WT T cells had enhanced IL-2 production when treated with inhibitor #52642 (Fig. 3.9B).  
 
 
 
 
 
FIGURE 3.9 Putative Cbl-b inhibitor #52642 enhances proliferation and IL-2 production in 
CD4+ and CD8+ T cells. (A) CD8+ T cells isolated from mice were grown in culture, labeled with 
CFSE, pre-treated with DMSO or putative Cbl-b inhibitor #52642, and assessed for proliferation after 
24 hours.  (B) WT CD4+ and CD8+ T cells were pre-treated with putative inhibitors for 2 hours, 
stimulated with plate-bound anti-CD3, and their supernatant assayed for IL-2 production by ELISA.  
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87675 enhances NK and T cell effector functions and may be more specific for 
Cbl-b  
CD4+ and CD8+ T cells isolated from WT mice were grown in culture, treated with 
a Cbl-b inhibitor, stimulated with either anti-CD3 or both anti-CD3 and anti-CD28, and 
assessed for IL-2 production after 24 hours. Putative Cbl-b inhibitors #87675 and 
#119012 increased IL-2 production by TCR-stimulated CD4+ and CD8+ T cells. 
(Fig.3.10A-B).  
 
 
 
 
 
To test whether the Cbl-b inhibitors were specific for Cbl-b, Cbl-b KO CD4+ and 
CD8+ T cells were pre-treated with either DMSO or inhibitor followed by stimulation with 
FIGURE 3.10 Putative Cbl-b inhibitors #87675 and #119012 increased IL-2 production by 
TCR-stimulated CD4+ and CD8+ T cells. (A) CD4+ and (B) CD8+ T cells were purified and pre-
treated with DMSO or putative Cbl-b inhibitors (10 μM) for 2 hours and stimulated in plates 
coated with PBS, anti-CD3, or anti-CD3/CD28. IL-2 was measured in the supernatant 24 hours 
later by ELISA.  
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anti-CD3. Both CD4+ and CD8+ WT and Cbl-b KO T cells had enhanced IL-2 production 
when treated with inhibitor #87675 (Fig. 3.11A-B). As with NK cells, the Cbl-b inhibitors 
enhanced T cell effector functions but were not specific to Cbl-b in T cells; further 
providing evidence that the inhibitor is not specific to Cbl-b. However, when the data was 
graphed as percent of control DMSO, Cbl-b KO CD4+ and CD8+ T cells had less IL-2 
production compared to WT CD4+ and CD8+ T cells. The latter suggests that the inhibitor 
is targeting Cbl-b, as well as other proteins (Fig. 3.11C).  
 
 
 
 
 
FIGURE 3.11. Putative Cbl-b inhibitors #87675 enhanced IL-2 production in Cbl-b 
WT T cells more so than in Cbl-b KO T cells. (A) CD4+ and (B) CD8+ T cells from WT 
and Cbl-b KO mice were purified and pre-treated with DMSO or putative Cbl-b inhibitors 
(10 μM) for 2 hours and stimulated with plates coated with PBS or anti-CD3. IL-2 was 
measured in the supernatant 24 hours later by ELISA. (C) Data are represented as % of 
control.   
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Cbl-b inhibitor #52642 does not reduce tumor burden in a mouse model of lung 
adenocarcinoma  
Inhibitor #52642 was not specific for Cbl-b. Cbl-b is homologous to c-
cbl; therefore, it is highly possible that the compound is also inhibiting c-Cbl. However, 
because both NK and T cell effector functions were enhanced and c-Cbl is another 
target for therapeutic inhibition, we decided to test the inhibitor in vivo as a potential 
immunotherapy. We selected the TC-1 murine lung adenocarcinoma cell line, as it has 
been established as an adequate subcutaneous tumor model and is sensitive to tumor 
killing by CD8+ T cells and NK cells deficient in Cbl-b[60,75]. TC-1 cells were grown in 
culture and injected subcutaneously into the flank of mice. After tumors were of 
appreciable size 1 week after injection, mice were treated intraperitoneally with either 
vehicle or inhibitor #52642 twice daily and tumor volume assessed by calipers. After an 
approximately 2-week pre-clinical trial, the mice treated with inhibitor #52642 had no 
reduction in tumor volumes compared to control. Mice were euthanized after losing 20% 
of their initial body weight (Fig. 3.12). Initially, weights were being monitored as we 
predicted that if the inhibitor were working, mice would initially lose weight. However, the 
reduction in weight correlated with tumor growth and not therapeutic efficacy. 
 
   
FIGURE 3.12 Putative Cbl-b inhibitor #52642 is not toxic but also ineffective at reducing 
TC-1 tumor burden. 3 mice were treated with putative Cbl-b inhibitor #52642 and 2 mice 
were given vehicle (DMSO) control. After tumor engraftment, mice began treatment with 
#52642 twice daily. (A)Tumor volume and (B) body weight were measured daily. After 10 
days, mice were euthanized because of greater than 20% weight loss in the treatment group.  
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Our data support the hypothesis that Cbl-b is a therapeutic target, as both NK 
cells and T cells that are either Cbl-b-deficient or are inhibited by an E3 ligase inhibitor 
have enhanced effector functions. It is left to be determined if these inhibitors also target 
c-Cbl. Despite the lack of specificity to Cbl-b, having an inhibitor that also targets c-Cbl 
may prove beneficial. c-Cbl and Cbl-b are homologues that have overlapping roles, and 
both are expressed in T cells and NK cells. An inhibitor that targets Cbl-b and c-Cbl may 
have an additive effect in enhancing T and NK cell effector functions. In addition, an 
immense obstacle in moving forward is the currently short half-life of the compound 
tested in vivo. Once the half-life is prolonged, we can more accurately test in vivo the 
safety and efficacy of these inhibitors.  
Discussion  
Ubiquitination is a post-translational modification that regulates intracellular 
protein levels and localization. Drug discovery in the ubiquitination field began to thrive 
with FDA approval of 26S proteasome inhibitors Bortezomib (approved in 2003, 
marketed as Velcade®) and more recently Carfilzomib (approved in 2012, marketed as 
Kyprolis®) for treatment of multiple myeloma. Although proteasome inhibitors 
demonstrate selectivity toward tumor cells and lead to apoptosis, they also suppress 
proteasome-mediated degradation of all intracellular proteins resulting in undesirable off-
target side effects[147]. In addition, many patients developed resistance towards 
Bortezomib[148]. Strategies to overcome the resistance include designing inhibitors with 
alternative mechanisms of action that differs from current targeting methods. For 
example, Carfilzomib covalently binds the proteasome, causing irreversible 
inhibition[149].  
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As part of the ubiquitination process, targeting E3 ubiquitin ligases represent 
another strategy for drug discovery. They are the largest family in the ubiquitin system - 
with 700 members predicted to have ligase activity. In addition, they use distinct catalytic 
mechanisms, making them targets that can yield enhanced specificity and less toxicity. 
Currently, there are few therapies targeting E3 ligases, and their development remains a 
challenge. Development of E3 ligase modulators is complicated by diverse protein–
protein interactions, lack of a classical enzymatic/catalytic active site, and specificity 
problems due to the variety of potential substrates.  
Despite these challenges, there are examples of successes. RING-type E3 
ligases were successfully targeted using small molecule inhibitors of protein–protein 
interactions, i.e., binding at substrate/receptor HIF1α/VHL[150], p53/MDM2 and 
p53/MDM4 interfaces[151], adaptor/receptor interface Skp1/Skp2[152] and several 
others[153]. However, no inhibitor has successfully been designed to specifically block 
E3 ligase activity.  
To successfully address this problem one must take into consideration the multi-
subunit nature of many E3 ligases that implies multiple druggable pockets and protein–
protein interfaces. To successfully inhibit an E3 ubiquitin ligase, an inhibitor should be 
designed to block the linker region containing the tyrosines that need to be 
phosphorylated to activate Cbl’s ligase function, the RF domain to prevent E2 binding, or 
block the TKB binding domain to prevent substrate binding. One potential caveat to 
inhibiting Cbl-b is that it plays many different roles, both in positively and negatively 
regulating cells. Cbl proteins have 3 roles: inhibitors, adaptors, and E3 ligases, making 
targeting them a difficult task.  We currently do not know enough of Cbl-b biology in NK 
cells and T cells to predict potential negative outcomes of Cbl-b inhibition.  
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Why did E3 ligase putative Cbl-b inhibitor #52642 enhance Cbl-b KO T and NK 
cells?  
Small molecule #52642 enhanced NK cell and T cell effector functions. However, 
it also enhanced effector functions in Cbl-b KO NK and T cells, indicating that the 
compound was not specific for Cbl-b. One likely explanation is that it is also targeting c-
Cbl, which is also expressed in both T cells and NK cells. The amino-terminal domains 
are highly conserved across all members of the Cbl family- making this explanation 
highly likely44. If an inhibitor is designed to target the RING finger domain, it is likely that 
it would inhibit both c-Cbl and Cbl-b as their C-termini are very similar. Cbl-b and c-Cbl 
are highly homologous proteins; therefore, it is possible that a small molecule inhibitor 
designed to bind to Cbl-b may also bind to c-Cbl.  One potential way to test this is 
developing siRNA to target Cbl-b and c-Cbl, transduce Jurkat T cells, and then measure 
IL-2 production levels by ELISA. As mentioned before, having an inhibitor that targets 
both c-Cbl and Cbl-b may be beneficial, as both play a role in negatively regulating 
lymphocytes.  
Why did E3 ligase inhibitor #52642 not work in vivo?  
Despite not being specific to Cbl-b, we predicted that the compound may still 
have an anti-tumor therapeutic effect in vivo given that it enhanced NK and T cell 
effector functions. We conducted a small pre-clinical study where we treated TC-1 lung 
adenocarcinoma bearing mice with vehicle or compound #52642. Although there was no 
toxicity associated with the compound, there was no therapeutic benefit compared to 
treatment with vehicle. There are several potential explanations for this.  
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The half-life of the compound was so short that the drug likely failed to enter 
enough cells and inhibit Cbl proteins despite intraperitoneal injections twice daily for the 
course of the study. The half-life of #52642 in vivo formulation was only 1.24 hrs, and the 
maximum concentration was shown to drop precipitously. In addition, the compound was 
not administered intravenously but via intraperitoneal injection. One consideration is that 
due to its short half-life, an intravenous injection may have worked better than an 
intraperitoneal injection. Putative Cbl-b inhibitor #87675 enhanced WT T cells more so 
than Cbl-b KO T cells and will, therefore, be a better option to test in vivo.  
How may the development of a Cbl-b inhibitor be accomplished? 
More than 20 small molecule inhibitors have been approved for clinical use and 
are being successfully used as therapies for cancer. Still, there are certain limitations 
that are to be considered and overcome while designing more active drugs so as to 
reduce the failure rates of the drugs at the clinical level. Certain small molecule inhibitors 
bind to multiple molecular targets including cell surface receptors and other intracellular 
proteins thus increasing the risk of toxicity[154]. Most of the small molecule drugs have a 
short life span, thus requiring daily dosing which is not the case with therapeutic 
monoclonal antibodies that have a longer life span[154]. Alternatively, coupling these 
drugs to other compounds, such as nano-carriers, so as to increase the specificity and 
bio-availability should be considered.   
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CHAPTER 4: DISCUSSION 
 
The human body needs internal rheostats to monitor responses to pathogens - 
those that are foreign, such as viruses, and even those that are derived from our own 
cells, such as tumors. With an internal rheostat, we can limit a pathogen and pathogen-
induced damage while at the same time avoiding autoimmunity. This requires sensors to 
monitor thresholds of activation on immune cells and to modulate the magnitude of their 
response. In addition, a physiological immune response requires a negative regulatory 
mechanism that provides a variety of safeguards and exit strategies. Several receptor 
families are required for homeostasis of the immune response. One such family is that of 
TAM receptors (Tyro3, Axl, Mer), which are receptor tyrosine kinases expressed in a 
variety of human and murine cell types.  
How receptor tyrosine kinases can act as sensors and at the same time promote 
signaling and cellular functions is a topic of immense interest, as RTKs are not typically 
associated with inhibiting signaling and cellular responses. According to the canonical 
view of RTKs as promoting signaling, the tyrosine kinase activity of TAM receptors 
activates ERK, AKT, and NFκB – key signaling pathways required for NK cell cytokine 
production[77]. Thus, it is puzzling that TAM receptors attenuate, rather than augment, 
NK cell function.  
TAM receptors are not the only puzzling RTKs with dual roles. Ron is an RTK 
that has been shown to negatively regulate macrophages. Ron induces transcription of 
E3 ubiquitin ligase SOCS1, which reduces the production and response to IFNγ, 
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resulting in enhanced susceptibility to endotoxin challenge[155]. TAM receptors have 
also been shown to negatively regulate DCs by increasing the transcriptional expression 
of E3 ubiquitin ligase SOCS1 and SOCS3[114]. Similarly, our data reveal a mechanism 
by which TAMs can inhibit activating receptor stimulation in NK cells. Namely, by 
phosphorylating and activating Cbl-b, TAM receptors can selectively suppress signaling 
through activating receptors by targeting LAT1 for degradation. Our data parallels the 
other established mechanisms by which RTKs (TAMs and Ron) can inhibit innate 
immune cell activation - via E3 ubiquitin ligases. Our data takes it a step further and 
identifies a target substrate of Gas6/TAM-activated Cbl-b, LAT1, which is required for 
the cytotoxic activity of NK cells. 
The role of RTKs in negatively regulating innate immunity: Unresolved questions 
and future directions  
Is the interaction between TAM and Cbl-b direct or indirect?  
We showed using recombinant proteins that Tyro3, Axl, and Mer can directly 
phosphorylate Cbl-b, specifically on tyrosines 133 and 363. In NK cells, we were able to 
show that incubation with Gas6 leads to phosphorylation of Cbl-b, and that 
phosphorylation was abolished with treatment with TAM inhibitor BMS777607. 
Nevertheless, this still does not prove that the phosphorylation is a result of a direct 
interaction. Even an immunoprecipitation of individual TAM receptors and 
immunoblotting for Cbl-b will not answer this question. Fluorescence resonance energy 
transfer (FRET) may provide a more definitive answer to this question. Yet, it is likely 
that given the supramolecular complexes that form at the immunological synapse, this 
story may be more complicated with other kinases being recruited to the phosphorylated 
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TAM receptor, thus making it difficult to answer the question of which kinase or kinases 
directly phosphorylate Cbl-b.  
 
What other signaling molecules downstream of the TAM/Cbl-b pathway aside from 
LAT1 are targeted by Cbl-b? 
It is debated whether LAT1 alone is enough to promote NK cell cytotoxicity, and 
there are reports that LAT2/NTAL is also required. We attempted to address this 
question but the antibodies available for LAT2/NTAL western blot provided inconclusive 
results (data not shown). In addition, it would also be important to test functionally 
whether LAT1 is indeed ubiquitinated upon Gas6/TAM stimulation and whether a LAT 
mutant (K52R or K204R) abrogates its ubiquitination and degradation. We attempted to 
perform a ubiquitination immunoprecipitation followed by LAT1 western blot but were 
unsuccessful. Several protocol details need to be optimized to improve the ubiquitination 
immunoprecipitation. The reverse experiment could not be done because the available 
LAT1 antibodies are not suited for immunoprecipitation. Similarly, we attempted to block 
the proteasome and lysosome to assess whether this would stabilize LAT1 levels upon 
Gas6 stimulation. However, this also requires optimization as the proteasome and 
lysosome inhibitors are toxic to NK cells, which are already in a stressed state upon 
serum and IL-2 starvation.  
Another way to test functionally whether LAT1 is required downstream of the 
Gas6/TAM pathway is by stimulating NK cells with a LAT1- independent method of 
stimulating NK cells, such as using IL-12 and IL-18. If the Gas6/TAM pathway requires 
LAT1, Gas6 should not inhibit cytokine production when stimulated by IL-12 and IL-18.  
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Aside from LAT1 and 2, there are likely other signaling molecules downstream of 
the TAM/Cbl-b pathway that may be targeted. Thus, along with LAT1, we also assessed 
the stability of other key signaling molecules that are required for NK cell activation, such 
as PLCγ1 and the p85 subunit of PI3K, after Gas6 stimulation. None of these proteins 
were degraded after 60 minutes of Gas6 stimulation. However, the lack of degradation of 
these proteins does not preclude them from being involved in the TAM/Cbl-b-mediated 
inhibition of NK cell activation. Ubiquitination can also lead to re-localization within the 
cell, can prevent proteins from binding to each other, and can also prevent the addition 
of post-translational modifications. Therefore, although PLCγ1 and p85 are not degraded 
upon Gas6 stimulation, Cbl-b may still be regulating NK cell responses by proteolysis-
independent mechanisms. An unbiased approach using tandem ubiquitin-binding entities 
(TUBES) or TUBES in combination with mass spectrometry may yield other targets of 
the TAM/Cbl-b pathway that may be required for NK cell cytotoxicity[156].  
How does the cellular environment affect TAM expression?  
To maintain homeostasis and prevent autoimmunity, it is imperative that the 
expression of immune modulating receptors be tightly regulated. In NK cells, TAM 
receptor expression may be minimal until required as would be the case in a pro-
inflammatory setting. We see examples of this regulation in macrophages and dendritic 
cells where TAM receptors are lowly expressed at baseline and expression is induced 
only when there are pro-inflammatory stimuli. In DCs, it is type 1 interferon receptor 
(IFNAR) signaling that upregulates Axl expression via the Janus kinase/signal 
transducers and activators of transcription (JAK/STAT) pathway[114]. In bone-marrow 
derived macrophages, surface expression of Axl is enhanced in a pro-inflammatory 
environment, such as in the presence of IFNs, IL-4, and Poly I:C[157]. The intracellular 
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mechanism that connects pro-inflammatory stimuli to enhanced expression of Axl is not 
yet known.  
It remains to be determined if TAM expression on NK cells requires induction by 
a pro-inflammatory environment. We and others have shown that NK cells minimally 
express TAM receptors[75] (data not shown). This provides some initial evidence that 
like macrophages and DCs, NK cells may need to be primed to express TAM receptors. 
Both DX5+ MACS purified NK cells and LAKs cultured in IL-2 express large amounts of 
phosphorylated Cbl-b protein even after resting from IL-2 for 4 hours. This became 
evident with the immunoprecipitation of Cbl-b, where there were high levels of 
phosphorylated Cbl-b protein being expressed at baseline (data not shown). This made 
it impossible to determine enhancement in phosphorylation with Gas6 treatment. There 
is evidence that NK cell stimulation can also lead to increases in total Cbl-b protein[76]. 
Therefore, one possibility is that this can this be due to IL-2 driven pro-inflammatory 
intracellular changes, which can lead to more Cbl-b being produced and/or being 
phosphorylated, either dependent or independent on TAM receptor expression.  
To test if TAM receptors are induced in a pro-inflammatory environment, better 
antibodies need to be developed as the current antibodies for murine TAM receptors are 
not adequate. If and when they are developed, a simple experiment would be to IL-2 
starve LAKs for 18 hours, serum starve them for 4 hours, and stain for TAM receptors 
after 0, 30, 60, and 120 minutes of pro-inflammatory cytokine stimulation, such as with 
IFNs or Poly I:C.  
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Is receptor mediated endocytosis of the Gas6/TAM complex required for TAM 
signaling?  
It is clear that NK cells that are deficient in Cbl proteins exhibit enhanced 
cytotoxicity, degranulation, anti-tumor effects, and cytokine production. The current 
hypothesis in the field is that upon Gas6/TAM ligation, Cbl-b gets recruited to 
ubiquitinate TAM receptors, and that receptor-mediated endocytosis of the Gas6/TAM 
complex is how Cbl-b negatively regulates NK cell activation[75]. Evidence was provided 
that TAM surface expression decreased over time with Gas6 ligation. However, no 
evidence was provided to show that the internalized Gas6/TAM complex is what drives 
the TAM-mediated anti-inflammatory program. This hypothesis was not unfounded as 
there are examples in the literature of Cbl proteins ubiquitinating and down-regulating 
cell-surface receptors. For example, c-Cbl can promote ligand-induced EGFR 
internalization in a ubiquitin-dependent manner, and either c-Cbl or Cbl-b can 
downregulate the TCR[58].  
In light of what we have learned, it is possible that Cbl-b ubiquitinates TAM 
receptors after the cell has had sufficient TAM/Cbl-b-mediated inhibition. This fits well 
with our model, where we show that Gas6-mediated TAM activation phosphorylates and 
activates Cbl-b, ubiquitinating LAT1, which is required for NK cell cytotoxicity. To ensure 
that a cell can mount a proper anti-inflammatory response when required, after sensing 
enough anti-inflammatory signals, Cbl-b ubiquitinates TAM receptors, leading to their 
endocytosis. This stops the anti-inflammatory program, which is required if the cell were 
to then encounter a virus or tumor and need to mount a proper inflammatory response. 
There is presently little evidence of TAM receptor-mediated endocytosis as a negative-
feedback mechanism. Another possible mechanism to halt signaling after a substantial 
 
 
78 
anti-inflammatory response is receptor shedding. Receptor shedding serves two 
purposes: 1) to remove the receptor and halt signaling and 2) to become a ligand sink, 
further preventing activation of receptors still present on the cell surface. There is 
evidence in macrophages that upon TAM stimulation, TAM receptors are shed[157]. 
Therefore, it is possible that negative feedback regulation of TAM signaling may be Cbl-
b-independent. More works needs to be done to further elucidate how TAM signaling is 
regulated in NK cells.   
We attempted to address the question of whether TAM receptor-mediated 
endocytosis was required for inhibition of NK cell effector functions. Receptor-mediated 
endocytosis can be clathrin-dependent or independent. The GTPase Dynamin has a role 
in both types of receptor-mediated endocytosis. Therefore, to address the question of 
whether Gas/TAM internalization is required for TAM’s inhibitory effect on NK cells, we 
used two dynamin inhibitors: Dyngo and Dynasaur. Unfortunately, because the 
compounds were too toxic to NK cells in serum-free conditions, the experiments did not 
yield any results as the cells died during incubation (data not shown). There is one 
published work using the human NK cell line NKL which used a dynamin inhibitor 
successfully, however, in serum sufficient media conditions[158]. It is likely that serum is 
required for cellular uptake of these compounds, in which case these experiments could 
not be performed as serum contains TAM ligands Gas6 and ProteinS.  
In addition to the potential toxic effects of using these compounds, dynamin 
inhibitors Dyngo and Dynasaur have also been shown to block the release of cytotoxic 
granules. Dynamin 2 was shown to regulate granule exocytosis during NK cell 
cytotoxicity[159]. Therefore, we would not have been able to use CD107a as a surrogate 
for cytotoxicity, nor could we assess perforin release. IFNγ, once it is produced, is also 
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transported via vesicles to the cell surface where it is released. Cytokine secretion is a 
distinct process from secretion of cytotoxic granules[160]; however, in human NK cells, 
clathrin is also required for IFNγ release after viral stimulation[161].  Both the issues of 
dynamin-inhibitor toxicity and the likely dependence on dynamin for both IFNγ and 
CD107a release make it difficult to answer the question of whether receptor-mediated 
endocytosis of the Gas6-TAM complex is a requirement for TAM’s inhibition of NK cell 
effector functions. 
Based on our model, receptor-mediated endocytosis may be part of the negative 
feedback mechanism to attenuate TAM signaling. There are several examples of ligand 
exposure leading to the downregulation of the ligand’s receptor as a means to stop 
signaling via that particular receptor. After an adequate anti-inflammatory response, Cbl-
b may ubiquitinate TAM receptors, allowing for their degradation and a return to cellular 
homeostasis.  
Does Cbl-b play a role in TAM-mediated phagocytosis by macrophages?  
Although there is insufficient evidence to validate Penninger’s group’s 
speculation that Cbl-b ubiquitinates TAM receptors and this internalized complex leads 
to negative regulation of signaling in NK cells, this interaction may occur in 
macrophages. TAM receptors and Cbl-b are both expressed in macrophages. Mer was 
shown to be the key TAM receptor required for phagocyte-dependent clearance of 
apoptotic cells[162], but since then all TAM receptors have been shown to play a role in 
phagocytosis[163,157]. Macrophages use TAM receptors to sense the PS exposed on 
the surface of apoptotic cells, but what occurs downstream of the TAM receptors is 
unknown. Given our data and that of others showing the importance of Cbl-b in TAM 
signaling, we hypothesized that Cbl-b is required for macrophages to phagocytose 
 
 
80 
apoptotic bodies via TAM receptors.  To test this, we performed an initial experiment 
where CFSE-labeled irradiated splenocytes were injected IV into WT and Cbl-b KO 
mice. If Cbl-b is required for macrophages to clear these apoptotic cells, we would have 
observed less CFSE+ cells in Cbl-b KO mice compared to WT. However, we observed 
no difference in CFSE+ cells in Cbl-KO and WT mice. Not surprisingly, this can be due 
c-Cbl functioning in the absence of Cbl-b. It has been shown before that c-Cbl and Cbl-b 
have redundant functions and either can ubiquitinate and down-regulate TCR[58]. This 
experiment, therefore, would need to be performed in Cbl-b and c-Cbl DKOs to answer 
this question.  
It would also be interesting to further elucidate the possible interaction between 
TAM receptors and Cbl-b. Based on in vitro data we and others have shown, Cbl-b 
ubiquitinates TAM receptors[75]. To further validate this data, it should be determined 
which lysines on Tyro3 can be possibly ubiquitinated by Cbl-b. Tyro3 has 12 lysine 
residues in the intracellular portion of the receptor. Truncation mutations of Tyro3 can 
help delineate which residue(s) are required for it to be ubiquitinated. If a ubiquitinated 
resistant Tyro3 can then be transduced into a cell line lacking all TAM receptors but 
expressing Cbl-b, then we could ask whether TAM receptors directly interact with Cbl-b 
and if Cbl-b provides a negative feedback mechanism to attenuate TAM signaling.  
 
Do TAMs play a role in NK cell sensing of apoptotic bodies?  
TAM receptors have many roles in maintaining homeostasis, not only in 
regulating intracellular signaling and innate immune effector functions, but also in the 
clearing of apoptotic bodies. When cells undergo apoptosis, apoptotic bodies express 
the “eat me” signal phosphatidylserine (PS) on their surfaces, which bind to serum Gas6. 
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Therefore, we speculate that this PS bound to Gas6 can bind to TAM receptors on the 
NK cell surface, inhibiting NK cell function.  
It is known that interaction between NK cells and macrophages is contact-
dependent[164,165], making the PS-Gas6-TAM receptor interaction likely. One possible 
rationale for this interaction is to prevent NK cells from killing something that is already 
dead. One possible experiment to test this would be to co-culture NK cells with a tumor 
line that expresses an NK receptor ligand, such as Rae1-RMA - a murine lymphoma cell 
line. Rae1-expressing RMA cells are known to activate NK cells by binding to and 
stimulating the NKG2D activating receptor[166]. If Rae1-RMA cells are irradiated to 
induce apoptosis and co-cultured with NK cells, the question would be whether Gas6 
present in the serum will bind to PS on the apoptotic cell and inhibit NKG2D-mediated 
NK cell activation. One caveat to this experiment is that NK cells likely express a 
receptor that directly binds to PS[167], as we discovered when attempting to make PS-
Gas6 liposomes and our PS only control inhibited NK cell activity (data not shown)[168].  
Targeting NK cells for therapies - unresolved questions and future directions  
NK cells represent a promising target for treatment of tumors and chronic 
infections. Although NK cell responses alone are often suboptimal to control tumor 
growth or viral infections, NK cells complement the activity of CD8+ T cells. This is 
especially true in settings where CD8+ T cells are no longer effective. Thus, strategies 
that enhance NK cell activity are necessary to fully harness their therapeutic potential. In 
this thesis, we have discussed how targeting negative regulators can be employed to 
enhance NK cell function. Manipulation of inhibitory signaling pathways is an attractive 
approach, but the research thus far is limited to mouse models and in vitro human NK 
cell activation. Most of the strategies currently being tested at the bedside involve the 
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manipulation of cell surface receptors and cytokines to enhance the activity of NK cells 
in neoplastic settings. None of the strategies are yet fully optimized nor are they 
effective; therefore, the development of novel inhibitors of signaling pathways (e.g., DGK 
and Cbl) and the targeting of inhibitory receptor/ligand pairs will likely improve the 
effectiveness of NK cell-based immunotherapy.   
Both Cbl-b and TAM receptors have dual roles in cancer: they individually drive 
tumorigenesis and act on immune cells to suppress an anti-tumor response, making 
them exciting targets for targeted anti-tumor immunotherapy. Using these therapies to 
specifically enhance an immune response can be even more beneficial because these 
therapies can in theory be used to treat a variety of different tumor types. In addition, 
because they’re enhancing immune responses, not only can cancers be treated, but also 
difficult-to-treat viral infections where enveloped viruses mimic apoptotic cells, 
expressing PtdSer on their surface[169]. In this setting, Axl has been shown to be 
involved in T cell priming and antiviral immunity[170].  It is unknown whether NK cells 
are also involved, thus it would be interesting to study the role of TAM receptors in NK 
cell antiviral immunity.  
As discussed previously in the introduction, RTKs are known to enhance 
signaling. As such, TAM receptors promote proliferation and survival via the ERK and 
AKT pathways. Not surprisingly, TAM receptors promote tumor growth, 
chemoresistance, metastasis, migration and invasion. There are no known mutations 
that make TAMs oncogenic like other RTKs. Their oncogenic potential is related to 
aberrant regulation of the same signaling pathways and cellular processes in which 
these receptors normally play a role[77]. This aberrant regulation leads to 
overexpression of TAMs.  
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It has been difficult to study immune cell TAM signaling in the context of cancer 
because both tumors and innate immune cells express TAM receptors. Gas6 is 
produced in the tumor microenvironment of melanoma and breast cancer tumors[171]. 
Gas6 promotes tumor survival and proliferation and inhibits the inflammatory innate 
immune response required for activation of anti-tumor cytotoxicity.   
The first study showing that TAM signaling affects anti-tumor immunity came 
from Gas6 KO mice, which had impaired primary tumor and metastatic growth[172]. In 
this setting, tumors produced IL-10 and macrophage colony-stimulating factor (M-CSF), 
which instructed macrophages in the microenvironment to overexpress and secrete 
Gas6. This Gas6 then acts on TAM receptors present on tumor cells. Stromal cells have 
also been shown to produce Gas6 in the presence of multiple myeloma and metastatic 
prostate cancer[173]. Therapeutically targeting Gas6/Axl using an Axl inhibitor has been 
shown to improve the efficacy of chemotherapies[174], likely due to enhancement of 
immune cell responses in addition to targeting tumors that may have developed 
resistance to standard chemotherapies.  
There is a plethora of TAM receptor inhibitors currently in development and in 
clinical trials[77]. Regulators of TAM receptors may also be another option for targeted 
therapies, such as the E3 ubiquitin ligase Cbl-b[75].   
TAMs and Cbl-b as therapeutic targets to enhance an immune response  
The activation of costimulatory T cell pathways is already used clinically for the 
treatment of cancers. Cbl-b would be another target for immunotherapy, as mice 
deficient in Cbl-b are able to spontaneously reject tumors of solid and hematopoietic 
types, including rejection of TC-1, EL-4, and E.G7 tumorigenic cell lines. Studies have 
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shown that this can be ascribed to both CD8+ and NK cells deficient in Cbl-b[32]. RNAi 
mediated knockdown of Cbl-b in adoptively transferred CD8+ T cells has been shown to 
be effective treatment for leukemia[140]. The development of small molecule inhibitors 
would be even more effective because it they can potentially enhance the anti-tumor 
activity of both T cells and NK cells.  
What are the different ways Cbl-b can be targeted?  
Cbl-b was discovered as an oncogene, where v-Cbl, a truncated splice variant 
containing only the TKB domain, caused leukemia in mice[175]. This truncated mutant 
prevented RTK ubiquitination and downregulation, mostly likely acting as a dominant-
negative protein preventing the recruitment of endogenous Cbl proteins to the RTK. 
Other mutants that have been identified have in-frame deletions of part or all of the linker 
and RF domains, losing E3 ligase activity; the latter resulting from point mutations which 
lead to mis-splicing of the Cbl mRNA[47].  
Interestingly, mice that lack Cbl proteins do not develop leukemia, yet mice that 
have a knock-in mutation of an RF-mutant Cbl develop myeloid leukemia[176]. The latter 
is likely due to a dominant negative effect, where mutant Cbl binds to activated RTKs, 
preventing recruitment of endogenous WT Cbl proteins. In fact, mice deficient in both c-
Cbl and Cbl-b in the hematopoietic stem cell compartment develop myeloid 
leukemia[177]. In addition to these mutations, Cbl proteins maintain their positive 
adaptive function - contributing to the transforming capacity of the Cbl mutants. 
Therefore, a novel approach would be to also target the adaptor function of Cbl protein.   
Progenra, Inc. has developed numerous small molecule peptides to bind Cbl-b 
and inhibit its ability to function as an E3 ubiquitin ligase. Whether these small molecules 
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bind the TKB domain and block interaction with tyrosine kinases has yet to be 
determined. In collaboration with Progenra, Inc., we tested dozens of these compounds. 
There is one promising compound (#87675), which although it is efficacious in vitro, has 
yet to be tested in vivo. Currently, an in vivo formulation is being made to test in the near 
future.  
Concluding thoughts  
NK cells represent a promising target for treatment of tumors and chronic 
infections. They are safer than T cell therapies and can function when T cells are no 
longer adequately killing tumors. Thus, strategies that involve the enhancement of NK 
cell activity are necessary to fully harness their therapeutic potential. 
Over the last decade, small molecule cancer drugs have been slowly replacing 
conventional chemotherapy. RTKs have been the main focus of molecularly targeted 
therapy using small molecule inhibitors, as they are usually deregulated in cancer and 
promote cancer cell survival and proliferation. Identifying regulators of RTKs and 
understanding the mechanism(s) underlying the negative regulation of innate immune 
responses will help in the design of novel strategies to further improve the efficacy of 
current drugs and possibly identify other novel targets. The advantages of using a 
combination of different agents that inhibit several pathways or use of small molecule 
inhibitors in combination with radiation therapy can also be explored. In this regard, 
combination therapies using small molecule drugs and monoclonal antibodies have been 
exploited and are emerging to be a promising anti-cancer strategy[178,179].  
We have explored how an RTK (TAM receptors) and a regulator of RTKs (Cbl-b), 
can work together to inhibit NK cell signaling, and we tested therapeutic inhibition of Cbl-
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b. Here, we provided a molecular mechanism which A) discusses the interaction 
between two clinical targets and B) provides a detailed mechanism that allows for further 
manipulation of inhibitory pathways to both target cancer cells and enhance antitumor 
immunity.  
More work needs to be done to further understand what other signaling 
molecules play a role in the TAM/Cbl-b pathway. This information can help determine 
what other effects in addition to providing other therapeutic targets. Potential therapies 
targeting either TAM receptors or Cbl-b will affect other players in the pathway. In 
addition, this pathway may play a role in other cell types, such as macrophages.  
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CHAPTER 5: Materials and Methods 
Mice 
Cbl-b KO mice were generated and generously provided by Richard Hodes (National 
Cancer Institute, Bethesda, MD). SJL/Thy1.1 were created by breeding B6.SJL and 
B6.PL1 mice. B6.SJL, B6.PL1, and C57BL/6 mice were purchased from The Jackson 
Laboratory. Mice were sacrificed and analyzed between 8 and 12 weeks of age. Mice 
were housed in pathogen-free conditions and treated in strict compliance with the 
Institutional Animal Care and Use Committee regulations at the University of 
Pennsylvania. 
Reagents, Flow cytometry, antibodies, and data analysis 
Recombinant murine Gas6 was purchased from R&D systems (Minneapolis, MN). 
Recombinant Axl and Mer were purchased from SignalChem (Richmond, BC, Canada). 
TAM inhibitor BMS777607 was purchased from Santa Cruz Biotechnology (Dallas, TX). 
Antibodies for NK cell stimulation and phenotyping were purchased from BD 
Pharmingen (San Diego, CA), BioLegend (San Diego, CA), eBioscience (San Diego, 
CA), Bio X Cell (West Lebanon, NH), and Molecular Probes, Invitrogen (Carlsbad, CA). 
Western blot antibodies were purchased from Cell Signaling Technology (Danvers, MA), 
Santa Cruz Biotechnology (Dallas, TX), or Sigma Aldrich (St. Louis, MO). All chemicals 
are from Sigma Aldrich (St. Louis, MO), unless otherwise specified.  
For flow cytometric analysis, single-cell suspensions were stained with fluorochrome-
labeled antibodies in PBS for 30 minutes at 4 ̊C. Fc receptors were blocked with anti-
CD16/32 antibodies (BD Pharmingen). For staining of LAKs, fluorochrome-labeled 
antibodies against CD4, CD8, NK1.1, and NKG2D (BD Pharmingen) were used, 
including Live/Dead (Invitrogen). Data were acquired using a multicolor flow cytometer 
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FACS Canto equipped with FACSDiva software (BD Biosciences). Data analysis was 
performed using FlowJo (BD Biosciences).  
Statistical Analysis  
Data are shown as mean values ± SEM. Illustrations and statistical analyses were 
generated using GraphPad Prism 4 (GraphPad, San Diego, CA). A p value <0.05 was 
considered to indicate statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001).  
Recombinant protein-specific protocols: 
Production and purification of proteins 
Human Cbl-b TKB+RF (residues 38-429) and Tyro3 kinase catalytic domain (residues 
495-810) were cloned into pET-24d(+)-based vectors for bacterial expression. Full length 
versions of these constructs do not grow adequately in bacteria. Tyro3 isolated from E. 
coli was found to be in a phosphorylated state, possibly due to autophosphorylation. 
Kinase-dead Tyro3 is not phosphorylated in bacteria (data not shown). Cbl-b point 
mutations (Y106F, Y133F, and Y363F), in addition to a compound mutant 
(Y106/133/363F) were generated from plasmid pE-10xHis-HA-Cbl-b TKB+RF by site-
directed mutagenesis. WT and mutant Cbl-b TKB+RF proteins were purified from IPTG-
induced bacteria transformed with the various constructs. The cells were lysed and 
sonicated for 30 seconds x 3 cycles, loaded onto HIS-select spin columns (Sigma), and 
purified according to the manufacturer’s protocol. To remove the imidazole contained in 
the elution buffer prior to assays, buffer exchange was performed using NAP-5 
Sephadex G-25 columns (GE Healthcare) using 20 mM Tris HCl pH 8.0. Proteins were 
stored in 150 mM NaCl, 10% glycerol, and 10mM DTT for stability. Protein concentration 
was measured using Pierce 600 nm kit (Thermo Scientific). 
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Phosphorylation and ubiquitination assays 
For in vitro kinase assays, ATP (0.2 mM), WT or mutant Cbl-b recombinant protein (500 
nM), and p-Tyro3 (50 nM), p-Axl (100nM), or p-Mer (100nM)  were added to a final 
volume of 50 mL in kinase assay buffer (50 mM Bicine pH8.0, 5 mM MgCl2, 0.05% 
Chaps, and 1mM beta-mercaptoethanol) and incubated at 25 ̊C for 1 hour. 
For ubiquitination assays, E1 (5 nM), E2 (100 nM), ATP (0.2 mM), ubiquitin (600 nM), p-
Tyro3 (50 nM), and Cbl-b (50 nM) were incubated in kinase assay buffer for 1 hour at 
room temperature in a final volume of 20 mL. The E2 enzyme used in the assays was 
UBE2D3/UbcH5C (LifeSensors). The reactions were stopped with 4X sample buffer 
(NuPage) with 100 mM DTT and immunoblotted with anti-phosphotyrosine or with anti-
ubiquitin. 
To assess whether the Cbl-b inhibitors could block E3 ubiquitin ligase activity, 200 nM 
recombinant purified cytoplasmic domain of Tyro3 was bound to clear polypropylene 96-
well plates overnight. Plates were washed 3X in PBST then blocked with 3% BSA in 
PBS for 2 hours. After blocking, plates were washed 3X in PBST and a mixture 
containing E1, E2, ATP, MgCl2 and a 1:5 ubiquitin:biotinylated-ubiquitin mix was added 
to all wells of the plate. Cbl-b was pre-incubated with indicated concentrations of 
compound (DMSO volume adjusted accordingly) for 30 minutes and then added to the 
reaction plate. Plates were incubated at 25 ̊C for 45 minutes and then washed 3X with 
PBST. Ubiquitylation was detected with streptavidin-HRP luminescence.  
To test whether the small molecules generated by Progenra, Inc. could inhibit Cbl-b 
mediated Tyro3 ubiquitylation, ubiquitylation reactions were performed using E1, E2, 
ATP, MgCl2, GST-Cbl-b, and HA-Tyro3 in the presence of indicated compounds or 
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vehicle control. Reaction was stopped at 1h with SDS sample buffer. Reactions were run 
on a 10% SDS-acrylamide gel and transferred for Western blot analysis. Membranes 
were then blotted with anti-HA primary, HRP secondary and signal was detected by 
chemiluminescence. 
To verify that Cbl-b inhibitors inhibit E3 and not E1 or E2 proteins, an in vitro inhibition 
assay was prepared using E1, E2, ATP, MgCl2, and a 1:4 mixture of WT ubiquitin and 
biotinylated ubiquitin. The mixture was incubated for 3 hours at 25 ̊C in the presence or 
absence of indicated concentrations of compound. After 3 hours, the reaction was 
stopped using 2X SDS containing sample buffer, ran on a 10% SDS-acrylamide gel and 
transferred for Western blot analysis. Membranes were then blotted with streptavidin-
conjugated HRP and signal was detected by chemiluminescence. 
NK cell-specific protocols:  
NK cell isolation and LAK preparation  
Splenocytes from 10-12 week old WT or Cbl-b KO mice were removed and crushed with 
the back end of a 1ml syringe in 1mL of ammonium-chloride- potassium (ACK) lysis 
buffer made in-house, resuspended in complete LAK media, and filtered using 70 micron 
filter paper. Complete LAK media consists of MEMα, 10 mM HEPES, 10% FBS, 1% 
penicillin/streptomycin, 1% L-glutamine, and 1 x 10-5M beta-mercaptoethanol. 
Splenocytes were then stained with 5uL of  anti–DX5-biotin antibody in 500mL of 
complete LAK media for 20 minutes in 4 ̊C, washed in LAK media, and enriched using 
70uL of anti-biotin MACS beads (Miltenyi Biotec) in 430 mL of MACS buffer (PBS, 0.5% 
BSA, 0.5 mM EDTA) for 30 minutes in 4 ̊C prior to magnetic separation. The DX5+ cells 
were then expanded in LAK media with 1000 U/ml human IL-2 (PeproTech) for at least 5 
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days to create LAKs. After 5-6 days of expansion, ∼80–90% of the LAKs in culture were 
NK cells (CD4-CD8-NK1.1+).  
NK cell stimulation assays 
For NK cell activation, freshly isolated splenocytes (untreated or from Poly I:C-injected 
mice, 200 μg per mouse, injected i.p. 16 hours before harvesting) or LAKs were rested 
(deprived of IL-2 and serum) for 2 hours with 450 ng/mL Gas6 and then cultured with 
PE-labeled anti-CD107a (0.4 mg/ml), IL-2 (1000 U/ml), and brefeldin A (10 mg/ml) for 5 
hours in 96-well tissue culture plates that were pre-coated with antibodies against NK 
cell–activating receptors NK1.1 (PK136) or NKG2D (HMG2A) plated at 30 μg/ml 
overnight at 4 ̊C.  The plates were washed twice in serum free LAK media prior to adding 
the cells. Unstimulated and PMA/Ionomycin controls shown in the figures did not contain 
exogenous hIL-2. The cells were then stained with cell surface antibodies, fixed and 
permeabilized (BD Biosciences), intracellularly stained with anti-IFNγ antibody, and 
analyzed by flow cytometry. LAKS were gated by FSC/SSC, followed by singlet selection 
(FSC-W/FSC-H and SSC-W/SSC-H), exclusion of dead cells, and exclusion of CD4+ and 
CD8+ T cells. Splenocytes from Poly I:C-treated mice were gated by FSC/SSC, followed 
by singlet selection (FSC-W/FSC-H and SSC-W/SSC-H), exclusion of dead cells, and 
exclusion of CD3+ T cells, and gating on NK cells (DX5+/NKp46+) 
In experiments involving the TAM inhibitor BMS777607, splenocytes were preincubated 
with 100 nM of the inhibitor for 2 hours before stimulation, and the inhibitor was 
maintained throughout the assay. All experiments were performed in serum-deprived 
conditions during the stimulation to avoid contamination of our cultures with Gas6, which 
is present in FBS. When using LAK cells, the cells were starved of IL-2 for 2-18 hours 
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prior to stimulation, since long term culture in IL-2 led to high baseline levels of Cbl-b 
phosphorylation (data not shown).  
Western Blot and Immunoprecipitation 
For immunoprecipitation of phosphotyrosine, LAKs were serum-starved for 4 hours and 
IL-2-starved for 18 hours, followed by incubation with the proteasome inhibitor MG132 (5 
μM, SelleckChem) for 30 minutes and stimulation with 450 ng/mL recombinant murine 
Gas6 for various time points at 37 ̊C. In some experiments, cells were co-incubated with 
MG132 and the pan-TAM inhibitor BMS777607 (300 nM), 30 minutes prior to Gas6 
stimulation or incubated with anti-NK1.1 antibody (30 mg/ml) with or without 450ng/mL 
Gas6 for 60 minutes. Cells were washed in PBS and protein was extracted with protein 
lysis buffer (Pierce Crosslink Magnetic IP/Co-IP Kit; Thermo Scientific) containing a 
cocktail of protease and phosphatase inhibitors (dichloroisocoumarin, benzamidine 
hydrochloride, sodium orthovanadate, sodium pyrophosphate, and sodium fluoride). 
Lysis was performed on ice for 5 minutes while vortexing followed by the addition of 10 
μg deubiquitinating enzyme Usp2core (Life Sensors) for 1 hour at room temperature. 5 
μg of PY20 antibody was prepared for immunoprecipitation using Pierce Crosslink 
Magnetic IP/Co-IP Kit. Crosslinked antibodies were incubated with lysates overnight in a 
rotator at 4 ̊C. Samples were run on SDS-PAGE gels, transferred to nitrocellulose 
membranes, and blotted for Cbl-b.   
For western blot lysates, LAKs were IL-2-starved for 18 hours followed by serum-
starvation for 4 hours prior to stimulation with 450 ng/mL recombinant murine Gas6 for 
various time points at 37 ̊C. Cells were then washed with PBS. Protein was extracted 
using 1% NP-40 lysis buffer containing a protease inhibitor cocktail (Roche) and 
phosphatase inhibitors for 25 minutes on a rotator at 4 ̊C. Samples were run on SDS-
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PAGE gels, transferred to nitrocellulose membranes, and blotted for the indicated 
protein. The band intensity of LAT1 and the loading control β-actin were measured by 
ImageJ and the ratio was normalized to unstimulated conditions.  
T cell-specific protocols:  
T cell isolation 
Splenocytes from 10-12-week-old WT or Cbl-b KO mice were removed and crushed with 
the back end of a 1ml syringe in 1mL of ammonium-chloride- potassium (ACK) lysis 
buffer made in-house, resuspended in complete LAK media, and filtered using 70 micron 
filter paper. Complete LAK media consists of MEMα, 10 mM HEPES, 10% FBS, 1% 
penicillin/streptomycin, 1% L-glutamine, and 1 x 10-5M beta-mercaptoethanol. 
Splenocytes were enriched using 70uL of anti-biotin MACS beads (Miltenyi Biotec) in 
430 mL of MACS buffer (PBS, 0.5% BSA, 0.5 mM EDTA) for 30 minutes in 4 ̊C prior to 
magnetic separation. 
T cell stimulation  
A 96 well flat bottom plate was coated with anti-CD3 (1ug/mL) or anti-CD3 (1μg/mL) and 
anti-CD28 (1μg/mL) in PBS in 4 ̊C. T cells were pre-incubated with DMSO or 10μM of 
Cbl-b inhibitor for 2 hours at 37 ̊C. 100uL of 1 million cells/mL were added per well and 
incubated overnight, transferred to a V-bottom plate, and the supernatant harvested 24 
hours later for ELISA.  
ELISA 
 
NK cell work: LAKs made from either WT or Cbl-b KO splenocytes were deprived of 
serum and IL-2 for 2 hours and simultaneously pre-treated with 450 ng/mL murine Gas6 
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at 37 ̊C. Cell free supernatant was collected 24 hours later after stimulation with anti-
NK1.1 and anti-NKG2D, and IFNγ content was measured by ELISA (BioLegend).  
T cell work: CD4+ and CD8+ T cells from either WT or Cbl-b KO splenocytes were pre-
treated with 10μM of inhibitor for 2 hours and stimulated with either anti-CD3 or anti-CD3 
and anti-CD28 for 24 hours at 37 ̊C. Cell free supernatant was collected 24 hours later, 
and IL-2 content was measured by ELISA (eBioscience).  
Cell line work:  
Transfection 
Human cell line HEK 293T (293Ts) cells were grown in culture. 18 hours prior to 
transfection, 293Ts were plated at 1x105 cells/well in a 12-well plate. Cells were checked 
visually to see if they were approximately 70% confluent prior to transduction. 293Ts 
were transfected using liposomes in serum-free Opti-MEM media (Gibco) with 1μg of 
V5-Tyro3, HA-Ubiquitin, and either FLAG-tagged WT Cbl-b or C373A ligase mutant Cbl-
b. Protocol was followed according to the manufacturer’s instructions (Lipofectamine).  
Western blotting  
Immunoprecipitation with tag V5 (V5-Tyro3) was performed, followed by immunoblotting 
for HA (HA-ubiquitin) and V5 (V5-Tyro3) and FLAG (FLAG-Cbl-b) and V5 (V5-
Tyro3). Cells were then washed with PBS. Protein was extracted using 1% NP-40 lysis 
buffer containing a protease inhibitor cocktail (Roche) and phosphatase inhibitors for 25 
minutes on a rotator at 4 ̊C. Samples were run on SDS-PAGE gels, transferred to 
nitrocellulose membranes, and blotted for the indicated protein. The band intensity of 
V5-Tyro3 ubiquitination was measured by ImageJ.  
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Mouse model of TC-1 lung adenocarcinoma 
TC1 cells are primary C57BL/6 mouse lung fibroblasts co-transformed with an activated 
c-H-ras oncogene and the HPV-16 E6 and E7 oncoproteins[180]. Culture conditions and 
TC1 inoculation protocols have been described elsewhere[60]. 2.5 × 105 TC1 tumor cells 
were subcutaneously injected into the shaved left flank of young (8–12 wk old) mice 
using a 1-cc syringe and a 27-gauge needle. Tumor growth was monitored daily with a 
caliper. Because TC1 cells are derived from female mice, only female animals were 
used for the described experiments.   
TC1 tumors were allowed to grow for 1 week. We waited 24 hours after visible growth to 
inject intraperitoneally with the first dose of #52642. Compound #52642 was prepared in 
DMSO and Tween80, the mice weighed, volume of compound calculated and 
immediately injected intraperitoneally (0.1mL injected per 10g of body weight). 
Subsequently, #52642 was administered twice daily, once in the morning and once in 
the evening every day. Tumor volume was measured using the calculation: Volume 
(mm3) = (width)2 x length/2. Mice were euthanized in accordance with animal license 
protocols either when tumor volume reached 1 cm3 or weight loss exceeded 20% of 
body weight.  
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